UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☒~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

For the quarterly period ended ~~September 30, 2017~~March 31, 2020

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

For the transition period from to

Commission File Number: 001-37477

TELADOC HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware		04-3705970
(State of incorporation)		(I.R.S. Employer Identification No.)

2 Manhattanville Road, Suite 203
Purchase, New York		10577
(Address of principal executive office)		(Zip code)

~~(203)~~ (203) 635-2002

(Registrant’s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TDOC	The New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒⌧ No ☐◻

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒⌧ No ☐◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer	☐⌧	Accelerated filer	☒◻	Non-accelerated filer	☐◻	Smaller reporting company	☐
Emerging growth company ☒	~~(Do not check if a smaller reporting company)~~☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒⌧

As of ~~October 30, 2017,~~April 27, 2020, the Registrant had ~~56,961,275~~ 74,453,266 shares of Common Stock outstanding.

Table of Contents

TELADOC HEALTH, INC.

~~TELADOC, INC.~~

QUARTERLY REPORT ON FORM 10-Q

For the period ended ~~September 30, 2017~~March 31, 2020

TABLE OF CONTENTS

		Page Number

PART I	Financial Information	1 2
Item 1.	Financial Statements	1 2
	Consolidated Balance Sheets as of ~~September 30, 2017~~March 31, 2020 (unaudited) and December 31, ~~2016~~2019	1 2
	Consolidated Statements of Operations (unaudited) for the quarters ended March 31, 2020 and ~~nine months ended September 30, 2017 and 2016~~2019	2 3
	Consolidated Statements of Comprehensive ~~(Loss) Income~~Loss (unaudited) for the quarters ended March 31, 2020 and ~~nine months ended September 30, 2017 and 2016~~2019	3 4
	Consolidated ~~Statement~~Statements of Stockholders’ Equity (unaudited) for the ~~nine months~~quarters ended ~~September 30, 2017~~March 31, 2020 and 2019	4 5
	Consolidated Statements of Cash Flows (unaudited) for the ~~nine months~~quarters ended ~~September 30, 2017~~March 31, 2020 and ~~2016~~2019	5 6
	Notes to Unaudited Consolidated Financial Statements	6 7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20 21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34 30
Item 4.	Controls and Procedures	35 30
PART II	Other Information	36 31
Item 1.	Legal Proceedings	36 31
Item 1A.	Risk Factors	36 31
Item 6.5.	~~Exhibits~~Other Information	37 31
~~Exhibit Index~~Item 6.	38 Exhibits	33
~~Signatures~~Exhibit Index		41 33
Signatures		35

Table of Contents

PART I

~~PART I~~

FINANCIAL INFORMATION

ITEM 1. Financial Statements

TELADOC HEALTH, INC.

~~TELADOC, INC.~~

CONSOLIDATED BALANCE ~~SHEETS~~SHEETS

(In thousands, except share and per share data, unaudited)


	March 31,		December 31,
	2020		2019

Assets
Current assets:
Cash and cash equivalents	$	507,956	$	514,353
Short-term investments		2,819		2,711
Accounts receivable, net of allowance of $4,651 and $3,787, respectively		70,721		56,948
Prepaid expenses and other current assets		14,932		13,990
Total current assets		596,428		588,002
Property and equipment, net		10,092		10,296
Goodwill		734,386		746,079
Intangible assets, net		214,666		225,453
Operating lease - right-of-use assets		32,175		26,452
Other assets		15,330		6,545
Total assets	$	1,603,077	$	1,602,827
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	8,142	$	9,075
Accrued expenses and other current liabilities		71,927		49,848
Accrued compensation		17,095		31,258
Total current liabilities		97,164		90,181
Other liabilities		10,237		11,539
Operating lease liabilities, net of current portion		29,430		24,994
Deferred taxes		18,848		21,678
Convertible senior notes, net		447,221		440,410
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 74,076,286 shares and 72,761,941 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively		74		73
Additional paid-in capital		1,572,024		1,538,716
Accumulated deficit		(537,128)		(507,525)
Accumulated other comprehensive loss		(34,793)		(17,239)
Total stockholders’ equity		1,000,177		1,014,025
Total liabilities and stockholders’ equity	$	1,603,077	$	1,602,827

See accompanying notes to unaudited consolidated financial statements.

September 30,

December 31,

2017

2016

Assets

Current assets:

Cash and cash equivalents

$
83,119

$
50,015
Short-term marketable securities

89,758

15,793
Accounts receivable, net of allowance of $2,989 and $2,422, respectively

26,995

13,806
Prepaid expenses and other current assets

7,484

3,103
Total current assets

207,356

82,717
Property and equipment, net

9,627

7,479
Goodwill

498,549

188,184
Intangible assets, net

164,570

24,875
Other assets

822

415
Total assets

$
880,924

$
303,670
Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$
1,852

$
2,236
Accrued expenses and other current liabilities

24,137

7,981
Accrued compensation

14,854

8,856
Other debt - current portion

—

2,000
Total current liabilities

40,843

21,073
Other liabilities

7,555

7,609
Deferred taxes

14,416

1,694
Long term bank and other debt, net

166,938

42,424
Convertible senior notes, net

204,393

—
Commitments and contingencies

Stockholders’ equity:

Common stock, $0.001 par value; 100,000,000 shares and 75,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; 56,908,305 shares and 46,201,563 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively

57

46
Additional paid-in capital

710,010

435,551
Accumulated deficit

(267,194)

(204,726)
Accumulated other comprehensive income (loss)

3,906

(1)
Total stockholders’ equity

446,779

230,870
Total liabilities and stockholders’ equity

$
880,924

$
303,670

Table of Contents

TELADOC HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data, unaudited)


	Quarter Ended March 31,
	2020		2019
Revenue	$	180,799	$	128,573
Expenses:
Cost of revenue (exclusive of depreciation and amortization shown separately below)		72,382		44,677
Operating expenses:
Advertising and marketing		32,515		26,404
Sales		17,940		16,212
Technology and development		19,257		15,987
Legal and regulatory		1,222		1,586
Acquisition and integration related costs		3,664		1,012
General and administrative		45,120		35,982
Depreciation and amortization		9,710		9,600
Total expenses		201,810		151,460
Loss from operations		(21,011)		(22,887)
Interest expense, net		9,303		6,521
Net loss before taxes		(30,314)		(29,408)
Income tax (benefit) expense		(711)		742
Net loss	$	(29,603)	$	(30,150)

Net loss per share, basic and diluted	$	(0.40)	$	(0.43)

Weighted-average shares used to compute basic and diluted net loss per share		73,278,857		70,919,496

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

TELADOC HEALTH, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, unaudited)


	Quarter Ended March 31,
	2020		2019
Net loss	$	(29,603)	$	(30,150)
Other comprehensive loss, net of tax:
Net change in unrealized gains on available-for-sale securities		0		55
Cumulative translation adjustment		(17,554)		(3,843)
Other comprehensive loss, net of tax		(17,554)		(3,788)
Comprehensive loss	$	(47,157)	$	(33,938)

See accompanying notes to unaudited consolidated financial statements

Table of Contents

TELADOC HEALTH, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data, unaudited)


							��		Accumulated
				Additional					Other		Total
	Common Stock			Paid-In			Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital			Deficit		Loss		Equity
Balance of December 31, 2019	72,761,941		73		1,538,716			(507,525)		(17,239)		1,014,025
Exercise of stock options	671,279		0		14,830			0		0		14,830
Issuance of common stock upon vesting of restricted stock units	642,411		1		(1)			0		0		0
Issuance of common stock for Convertible Notes	655		0		58			0		0		58
Stock-based compensation	0		0		18,421			0		0		18,421
Other comprehensive loss, net of tax	0		0		0			0		(17,554)		(17,554)
Net loss	0		0		0			(29,603)		0		(29,603)
Balance as of March 31, 2020	74,076,286	$	74	$	1,572,024		$	(537,128)	$	(34,793)	$	1,000,177

Balance as of December 31, 2018	70,516,249	$	70	$	1,434,780		$	(408,661)	$	(13,070)	$	1,013,119
Exercise of stock options	564,102		1		8,853			0		0		8,854
Issuance of common stock upon vesting of restricted stock units	383,060		0		0			0		0		0
Stock-based compensation	0		0		13,523			0		0		13,523
Other comprehensive loss, net of tax	0		0		0			0		(3,788)		(3,788)
Net loss	0		0		0			(30,150)		0		(30,150)
Balance as of March 31, 2019	71,463,411	$	71	$	1,457,156	$		(438,811)	$	(16,858)	$	1,001,558

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

TELADOC HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)


	Quarter Ended March 31,
	2020		2019
Cash flows used in operating activities:
Net loss	$	(29,603)	$	(30,150)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		11,228		11,563
Allowance for doubtful accounts		1,247		783
Stock-based compensation		18,315		13,523
Deferred income taxes		(2,820)		(2,672)
Accretion of interest		6,859		6,060
Changes in operating assets and liabilities:
Accounts receivable		(17,219)		(8,251)
Prepaid expenses and other current assets		101		350
Other assets		137		30
Accounts payable		(502)		(28)
Accrued expenses and other current liabilities		21,565		14,530
Accrued compensation		(13,798)		(11,737)
Operating lease liabilities		(1,287)		(479)
Other liabilities		(543)		(1,414)
Net cash used in operating activities		(6,320)		(7,892)
Cash flows (used in) provided by investing activities:
Purchase of property and equipment		(962)		(571)
Purchase of internal-use software		(1,966)		(1,099)
Proceeds from marketable securities		0		9,000
Sale of assets		0		6
Pre-funding associated with the pending acquisition		(9,000)		0
Net cash (used in) provided by investing activities		(11,928)		7,336
Cash flows provided by financing activities:
Net proceeds from the exercise of stock options		14,889		8,854
Cash received for withholding taxes on stock-based compensation, net		164		1,848
Net cash provided by financing activities		15,053		10,702
Net (decrease) increase in cash and cash equivalents		(3,195)		10,146
Foreign exchange difference		(3,202)		(177)
Cash and cash equivalents at beginning of the period		514,353		423,989
Cash and cash equivalents at end of the period	$	507,956	$	433,958

Income taxes paid	$	0	$	23

Interest paid	$	0	$	0

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

~~TELADOC, INC.~~

~~CONSOLIDATED STATEMENTS OF OPERATIONS~~

~~(In thousands, except share and per share data, unaudited)~~

Quarters Ended September 30,

Nine Months Ended September 30,

2017

2016

2017

2016

Revenue

$
68,650

$
32,381

$
156,139

$
85,757


Cost of revenue

16,742

7,112

38,907

21,946

Gross profit

51,908

25,269

117,232

63,811

Operating expenses:

Advertising and marketing

14,328

9,046

39,222

24,900

Sales

11,393

7,662

26,705

18,792

Technology and development

9,964

5,867

24,013

15,921

Legal

105

1,033

725

3,348

Regulatory

777

817

2,771

2,437

Acquisition and integration related costs

8,526

6,196

10,639

6,959

General and administrative

21,938

12,298

52,299

35,215

Depreciation and amortization

6,418

2,607

11,693

5,673

Loss from operations

(21,541)

(20,257)

(50,835)

(49,434)

Amortization of warrants and loss on extinguishment of debt

1,457

8,454

1,457

8,454

Interest expense, net

8,202

873

9,678

1,707

Net loss before taxes

(31,200)

(29,584)

(61,970)

(59,595)

Income tax provision

130

188

429

360

Net loss

$
(31,330)

$
(29,772)

$
(62,399)

$
(59,955)

Net loss per share, basic and diluted

$
(0.55)

$
(0.65)

$
(1.15)

$
(1.46)

Weighted-average shares used to compute basic and diluted net loss per share

56,493,054

45,860,269

54,435,343

41,071,474

~~See accompanying notes to unaudited consolidated financial statements.~~

~~Table of Contents~~

~~TELADOC, INC.~~

~~CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)~~

~~(In thousands, unaudited)~~

Quarters Ended September 30,

Nine Months Ended September 30,

2017

2016

2017

2016

Net loss

$
(31,330)

$
(29,772)

$
(62,399)

$
(59,955)

Other comprehensive income (loss), net of tax:

Net change in unrealized gains on available-for-sale securities

(6)

(17)

(6)

50

Cumulative translation adjustment

3,913

—

3,913

—

Other comprehensive income (loss), net of tax

3,907

(17)

3,907

50

Comprehensive loss

$
(27,423)

$
(29,789)

$
(58,492)

$
(59,905)

~~See accompanying notes to unaudited consolidated financial statements~~

~~Table of Contents~~

~~TELADOC, INC.~~

~~CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY~~

~~(In thousands, except share data, unaudited)~~

Accumulated


Additional



Other

Total

Common Stock

Paid-In

Accumulated

Comprehensive

Stockholders’


Shares

Amount

Capital

Deficit

Income

Equity

Balance as of December 31, 2016

46,201,563

$
46

$
435,551

$
(204,726)

$
(1)

$
230,870

Exercise of stock options

734,293

1

6,995

—

—

6,996

Exercise of warrants

138,903

—

—

—

—

—

Issuance of common stock under employee stock purchase plan

90,968

—

1,265

—

—

1,265

Issuance of common stock for the acquisition of Best Doctors

1,855,078

2

66,178

—

—

66,180

Equity component of Convertible Senior Notes, net of issuance costs

—

—

62,404

—

—

62,404

Stock-based compensation (1)

—

—

13,697

(69)

—

13,628

Follow-On Offering

7,887,500

8

123,920

—

—

123,928

Other comprehensive income, net of tax

—

—

—

—

3,907

3,907

Net loss

—

—

—

(62,399)

—

(62,399)

Balance as of September 30, 2017

56,908,305

$
57

$
710,010

$
(267,194)

$
3,906

$
446,779

~~(1)~~

~~The $0.1 million adjustment to accumulated deficit represents the adoption of ASU 2016-09 for cumulative forfeitures expense. See Note 2 for additional information.~~

~~See accompanying notes to unaudited consolidated financial statements.~~

~~Table of Contents~~

~~TELADOC, INC.~~

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(In thousands, unaudited)~~

Nine Months Ended September 30,

2017

2016

Cash flows used in operating activities:







Net loss

$
(62,399)

$
(59,955)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

11,693

5,673

Allowance for doubtful accounts

1,343

1,970

Stock-based compensation

13,628

5,198

Deferred income taxes

225

360

Accretion of interest

3,262

29

Amortization of warrants and loss on extinguishment of debt

1,457

7,717

Changes in operating assets and liabilities:

Accounts receivable

(3,186)

(1,515)

Prepaid expenses and other current assets

(2,717)

(1,116)

Other assets

(89)

(18)

Accounts payable

(782)

(2,265)

Accrued expenses and other current liabilities

9,432

(462)

Accrued compensation

967

23

Other liabilities

0

20

Net cash used in operating activities

(27,166)

(44,341)

Cash flows (used in) provided by investing activities:

Purchase of property and equipment

(2,043)

(1,118)

Purchase of internal-use software

(1,473)

(852)

Purchase of marketable securities

(119,670)

(44,187)

Proceeds from marketable securities

45,820

95,604

Acquisition of business, net of cash acquired

(379,355)

(37,013)

Net cash (used in) provided by investing activities

(456,721)

12,434

Cash flows provided by financing activities:

Net proceeds from the exercise of stock options

6,996

2,209

Proceeds from issuance of convertible notes

263,722

—

Proceeds from borrowing under bank and other debt

166,679

29,490

Repayment of bank loan and other debt

(46,191)

(11,667)

Proceeds from issuance of common stock

123,928

250

Proceeds from employee stock purchase plan

1,265

—

Cash for withholding taxes on stock-based awards, net

495

591

Net cash provided by financing activities

516,894

20,873

Net increase (decrease) in cash and cash equivalents

33,007

(11,034)

Foreign exchange difference

97

—

Cash and cash equivalents at beginning of the period

50,015

55,066

Cash and cash equivalents at end of the period

$
83,119

$
44,032

Interest paid

$
4,727

$
1,734

~~See accompanying notes to unaudited consolidated financial statements.~~

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

Note 1. Organization and Description of Business

Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as ~~“Teladoc”~~“Teladoc Health” or the “Company”. The Company’s principal executive ~~offices are~~office is located in Purchase, New ~~York and Lewisville, Texas.~~York. Teladoc Health is the ~~nation’s largest telehealth company.~~global leader in providing virtual healthcare services with a focus on high quality, lower costs, and improved outcomes around the world.

On July 14, 2017, the Company completed the acquisition of Best Doctors Holdings, Inc. (“Best Doctors”), an expert medical consultation company focused on improving health outcomes for the most complex, critical and costly medical issues. See Note 3 “Business Acquisition”.

On January ~~24, 2017, Teladoc completed its follow on public offering (the “Follow-On Offering”) in which~~12, 2020, the Company ~~issued~~entered into a definitive agreement to acquire InTouch Technologies, Inc., the leading provider of enterprise telehealth solutions for hospitals and ~~sold 7,887,500 shares~~health systems. The transaction is expected to close in mid-2020. Under the terms of ~~common stock, including~~ the ~~exercise of an underwriter option to~~agreement, the purchase ~~additional shares, at an issuance~~ price of ~~$16.75 per share. The Company received net proceeds~~$600.0 million will consist of ~~$123.9~~approximately $150.0 million ~~after deducting underwriting discounts and commissions of $7.6 million~~in cash as well as ~~other offering expenses~~$450.0 million of ~~$0.6 million.~~

~~On July 1, 2016,~~Teladoc Health’s common stock which is subject to adjustment based on the ~~Company completed~~average of the ~~acquisitions of HY Holdings, Inc. d/b/a HealthiestYou Corporation (“HealthiestYou”), a telehealth consumer engagement technology platform~~Company’s stock price for the ~~small~~ten full trading days prior to ~~mid-sized employer market. Upon~~ the ~~effective date~~completion of the ~~merger, HealthiestYou merged with and into Teladoc. See Note 3 “Business Acquisition”.~~acquisition.

Note 2. Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. The interim results for the ~~quarters and nine months~~quarter ended ~~September 30, 2017~~March 31, 2020 are not necessarily indicative of results for the full ~~2017~~2020 calendar year or any other future interim periods. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Form 10-K for the year ended December 31, ~~2016.~~

2019

The unaudited consolidated financial statements include the results of Teladoc Health, its wholly owned subsidiaries, ~~two~~as well as 2 professional associations, ~~and twenty two~~14 professional corporations and a service corporation ~~(collectively, the~~(the “Association”).

Teladoc Physicians, P.A. became Teladoc Health Medical Group, P.A. on January 1, 2020. Teladoc Health Medical Group, P.A. is party to several ~~Services Agreements~~services agreements by and among it and the professional corporations pursuant to which each professional corporation provides services to Teladoc ~~Physicians,~~Health Medical Group, P.A. Each professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.

The Company holds a variable interest in the Association which contracts with physicians and other health professionals in order to provide services to ~~Teladoc.~~Teladoc Health. The Association is considered a variable interest entity (“VIE”) since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE, must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of the Association and funds and absorbs all losses of the VIE.

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

Total revenue and net ~~loss~~(loss) income for the VIE were ~~$6.9~~$42.5 million and ~~$(1.3)~~$(0.1) million, respectively, for the quarter ended ~~September 30, 2017~~March 31, 2020 and ~~$4.5~~$21.1 million and ~~$(2.2)~~$(0.1) million, respectively, for the quarter ended September 30, 2016. Total revenue and net loss for the VIE were $22.6 million and $(5.7) million, respectively, for the nine months ended September 30, 2017 and $15.5 million and $(5.7) million, respectively, for the nine months ended September 30, 2016.March 31, 2019. The VIE’s total assets were ~~$3.0~~$22.8 million and ~~$2.9~~$13.6 million at ~~September 30, 2017~~March 31, 2020 and December 31, ~~2016,~~2019, respectively. Total liabilities for the VIE were ~~$33.8~~$60.4 million and ~~$27.8~~$51.3 million at ~~September 30, 2017~~March 31, 2020 and December 31, ~~2016,~~2019, respectively. The VIE’s total stockholders’ deficit was ~~$30.7~~$37.8 million and ~~$25.0~~$37.7 million at ~~September 30, 2017~~March 31, 2020 and December 31, ~~2016,~~2019, respectively.

The functional currency for each of the Company’s foreign subsidiaries is the local currency. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet

Table of Contents

date. Revenues and expenses are translated at the weighted average exchange rate during the period. Cumulative translation gains or losses are included in stockholders’ equity as a component of accumulated other comprehensive income (loss).

The Company operates in a single reportable segment – health services. Revenue earned by foreign operations outside of the United States ~~which relate to Best Doctors,~~ were ~~$8.7~~$29.4 million and $25.2 million for the ~~quarter~~quarters ended March 31, 2020 and ~~nine months ended September 30, 2017 and zero in 2016.~~2019, respectively. Long-lived assets from foreign operations both totaled ~~$0.3~~$2.2 million as of ~~September 30, 2017~~March 31, 2020 and ~~zero as of September 30, 2016.~~December 31, 2019.

All intercompany transactions and balances have been eliminated.

Recently Issued Accounting Pronouncements

In December 2019, FASB issued ASU 2019-12 Simplification of Income Taxes (Topic 740) Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The ~~Company~~amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. We are early adopting ASU 2019-12 on our consolidated financial statements and disclosures effective January 1, 2020, with no material impact to the financial statements.

In January 2017, the FASB issued ASU 2017-04, Goodwill Simplifications (Topic 350). ASU 2017-04 simplifies the test for goodwill impairment. The new guidance eliminates Step 2 from the goodwill impairment test as currently prescribed in the U.S. generally accepted accounting principle. This ASU is the result of the FASB project focused on simplifications to accounting for goodwill. The new guidance was effective for the first quarter of 2020 and was adopted in the quarter-ended December 31, 2019.

In June 2016, the FASB issued ASU ~~2016-09, Compensation – Stock Compensation~~2016-13, Financial Instruments - Credit Losses (Topic ~~718): Improvements~~326) Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to ~~Employee Share-Based Payment Accounting during~~utilize a new impairment model known as the current expected credit loss ("CECL") model to estimate its lifetime "expected credit loss" and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The CECL model is expected to result in more timely recognition of credit losses. ASU 2016-13 requires new disclosures for financial assets measured at amortized cost, loans and available-for-sale debt securities. ASU 2016- 13 is effective for public companies for annual periods beginning after December 13, 2019, including interim periods within those fiscal years. The standard will apply as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance was effective for the first quarter of 2020 and was adopted in the quarter ended March 31, ~~2017 as described below.~~ 2020, with no material impact to the financial statements.

Summary of Significant Accounting Policies

There have been no ~~other~~ changes to the significant accounting policies described in the 2019 Form 10-K that have had a material impact on the consolidated financial statements and related notes.

~~Reclassifications~~

~~Certain prior year amounts have been reclassified~~ The Company has not experienced any significant impact to ~~conform to the current year presentation.~~

~~Recently Issued Accounting Pronouncements~~

~~In March 2016,~~ ~~the FASB issued~~ ~~ASU 2016-09,~~ ~~Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.~~ ~~ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards~~it’s estimates and assumptions as either equity or liabilities, and classification on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. On January 1, 2017, the Company adopted this standard on a modified retrospective basis. As a result of the ~~adoption of this standard, a deferred tax asset of approximately $1.3 million was recorded as a cumulative effect adjustment~~COVID-19 pandemic. On an ongoing basis, the Company will continue to ~~accumulated deficit.~~ closely monitor for any changes to the related impacts, especially on the allowance for doubtful accounts.

Note 3. Revenue

The Company generates virtual healthcare service revenue from contracts with clients who purchase access to the Company’s professional provider network or medical experts for their employees, dependents and other beneficiaries. The Company’s client contracts include a per-member-per-month subscription access fee as well as certain contracts that generate additional revenue on a per-telehealth visit basis for general medical, other specialty visits and expert medical service on a per case basis. The Company also has ~~also recorded~~certain contracts that generate revenue based solely on a ~~full valuation allowance~~per telehealth visit basis for general medical and other specialty visits. For the Company’s direct-to-consumer behavioral health product, members purchase access to the Company’s professional provider network for a subscription access fee. Accordingly, the Company generates subscription access revenue from subscription access fees and visit fee revenue for general medical, expert medical service and other specialty visits.

Table of Contents

The Company’s agreements generally have a term of one year. The majority of clients renew their contracts following their first year of services. Revenues are recognized when the Company satisfies its performance obligation to stand ready to provide telehealth services which occurs when the Company’s clients and members have access to and obtain control of the telehealth service. The Company generally bills for the ~~deferred tax asset due to~~telehealth services on a monthly basis with payment terms generally being 30 days. There are not significant differences between the uncertainty regarding the future realization and as a result, there was no change to stockholders’ equity. Additionally, the Company elected to change its policy from estimating forfeitures to recognizing forfeitures when they occur and recorded a cumulative adjustment to accumulated deficit of approximately $0.1 million as of January 1, 2017.

~~In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09,~~ ~~Revenue from Contracts with Customers~~ ~~(Topic 606), to achieve a consistent application~~timing of revenue recognition ~~within~~and billing. Consequently, the ~~U.S., resulting in~~Company has determined that client contracts do not include a ~~single revenue model to be applied by reporting companies under GAAP. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services~~financing component. Revenue is recognized in an amount that reflects the consideration ~~to which the entity expects to be entitled~~that is expected in exchange for ~~those goods~~the service and includes a variable transaction price as the number of members may vary from period to period. Based on historical experience, the Company estimates this amount.

Subscription access revenue accounted for approximately 76% and 82% of our total revenue for the quarters ended March 31, 2020 and 2019, respectively.

The following table presents the Company’s revenues disaggregated by revenue source (in thousands):


	Quarter Ended
	March 31,
	2020		2019
Subscription Access Fees:
U.S.	$	107,939	$	80,979
International		29,114		24,975
Visit Fee Revenue:
U.S. Paid Visits		30,898		18,248
U.S. Visit Fee Only		12,586		4,121
International Paid Visits		262		250
Total Revenues	$	180,799	$	128,573

As of March 31, 2020, accounts receivable, net of allowance for doubtful accounts, were $70.7 million. The allowance for doubtful accounts reflects our best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on historical experience, specific account information and other currently available evidence.

For certain services, payment is required for future months before the service is delivered to the client or member. The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. ~~In addition,~~The net increase of $5.4 million and $2.9 million in the ~~revised guidance requires that reporting companies disclose~~deferred revenue balance for the ~~nature, amount, timing,~~three months ended March 31, 2020 and ~~uncertainty of revenue~~2019, respectively, are primarily driven by the direct-to-consumer behavioral health product and cash ~~flows arising from~~payments received or due in advance of satisfying the Company’s performance obligations, offset by revenue recognized that were included in the deferred revenue balance at the beginning of the period. The Company anticipates that it will satisfy most of its performance obligations associated with the deferred revenue within the prospective fiscal year.

The Company’s contracts ~~with customers.~~do not generally contain refund provisions for fees earned related to services performed. However, the Company’s direct-to-consumer behavioral health service provides for member refunds. Based on historical experience, the Company estimates the expected amount of refunds to be issued which are recorded as a reduction of revenue. The ~~revised guidance is effective~~Company issued refunds of approximately $1.2 million and $0.6 million for the quarter ended March 31, 2020 and 2019, respectively.

Additionally, certain of the Company’s contracts include client performance guarantees that are based upon minimum Member utilization and guarantees by the Company ~~beginning in~~for specific service level performance of the Company’s services. If client performance guarantees are not being realized, the Company records, as a reduction to revenue, an estimate of the amount that will be due at the end of the respective client’s contractual period. For the quarter ~~ending~~ended March 31, ~~2018; early adoption is allowed. The revised guidance is required~~2020 and 2019, revenue recognized from performance obligations related to ~~be applied retrospectively to each~~ prior ~~reporting period presented~~periods for the aforementioned changes in transaction price or ~~modified retrospectively applied with the cumulative effect of initially applying it recognized at the date of initial application.~~ client performance guarantees, were not material.

The Company has ~~undergone~~elected the optional exemption to not disclose the remaining performance obligations of its contracts since substantially all of its contracts have a ~~process~~duration of ~~identifying~~one year or less and the ~~various types of revenue streams and has performed an initial evaluation~~variable consideration expected to be received over the duration of the ~~components of~~contract is allocated entirely to the wholly unsatisfied performance obligations.

Table of Contents

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

the associated contractual arrangements. As a result of the Best Doctors acquisition, the Company is in process of performing a similar assessment. The Company is assessing the impact of this standard on its revenue recognition policy and anticipates adopting the standard using the modified retrospective method.

~~In February 2016, the FASB~~ ~~issued~~ ~~ASU 2016-02,~~ ~~Leases (Topic 842). ASU 2016-02~~ outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of fiscal 2019. Early adoption is permitted. ~~The Company is currently in the process of evaluating the impact of the adoption of this standard on the consolidated financial statements.~~

Note 3.4. Business Acquisitions

On ~~July 14, 2017,~~April 30, 2019, the Company completed the acquisition of ~~Best Doctors through a merger~~the Paris-based telemedicine provider MedecinDirect in which ~~Best Doctors~~MedecinDirect became a wholly-owned subsidiary of the Company. The aggregate merger consideration paid was ~~$445.5~~$11.2 million net of cash acquired of $13.7 million, which was comprised of 1,855,078 shares of Teladoc’s common stock valued at $66.2 million on July 14, 2017, and $375.0 million of cash, subject to post-closing working capital adjustments as defined in the merger agreement. The post-closing working capital adjustment was finalized in the amount of $4.3 million. Best Doctors provides technology innovations and services to help employers, health plans and provider organizations to ensure that their members combat medical uncertainty with ~~access to the best medical minds.~~additional potential earnout consideration. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from ~~this~~the acquisition is not tax deductible. The total acquisition related costs of the acquisition were $9.1 million and included transaction costs for investment bankers and other professional fees. The Company recorded $21.8 million of revenue and $1.1 million of net income from Best Doctors for the quarter and nine months ended September 30, 2017.

On July 1, 2016, the Company completed the acquisition of HealthiestYou through a merger in which HealthiestYou became a wholly-owned subsidiary of the Company. The aggregate merger consideration paid was $151.5 million, which was comprised of 6,955,796 shares of Teladoc’s common stock valued at $108.3 million on July 1, 2016, and $43.2 million of cash, subject to post-closing working capital adjustments as defined in the merger agreement. The post-closing working capital adjustment was finalized in the amount of less than $0.1 million. HealthiestYou was a telehealth consumer engagement technology platform for the small to mid-sized employer market. Solutions provided by HealthiestYou included 24/7 access to telephone and video conferencing with doctors as well as the convenience of procedure price comparisons, prescription medicine price comparisons, health plan information and benefits eligibility and location information for wellness service providers. The acquisition was considered a stock acquisition for tax purposes and as such the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs of the acquisition were $6.9 million and included transaction costs for investment bankers and other professional fees as well as $5.7 million of contract termination costs for certain HealthiestYou third party providers. The contract termination costs of $5.7 million were previously accrued by HealthiestYou and reflected in HealthiestYou’s financial statements as of June 30, 2016, prior to the acquisition. These non-cash expenses are also reflected in the Company’s financial results in the quarter ended September 30, 2016 as the Company benefited from the termination of these contracts.

The acquisitions described above were accounted for using the acquisition method of accounting, which requires, among other things, the assets acquired and the liabilities assumed be recognized at their fair values as of the acquisition date. The results of the acquisitions were included within the consolidated financial statements commencing on the respective aforementioned acquisition dates.

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

The following table summarizes the fair value estimates of the assets acquired and liabilities assumed at each acquisition date. The Company, with the assistance of a third-party valuation expert, estimated the fair value of the acquired tangible and intangible assets.

~~Identifiable assets acquired and liabilities assumed (in thousands):~~

BestDoctors

HealthiestYou

Purchase price

$
459,225

$
151,484

Less:

Cash

13,690

6,204

Accounts receivable

11,205

1,184

Other assets

13,613

1,537

Client relationships

112,810

10,930

Non-compete agreements

-

70

Internal-use software

-

2,220

Trademarks

24,920

1,180

Accounts payable

(393)

(836)

Deferred taxes

(11,800)

—

Other liabilities

(12,337)

(2,847)

Goodwill

$
307,517

$
131,842

~~The amount allocated to goodwill reflects the benefits Teladoc expects to realize from the growth of the respective acquisitions operations.~~

The Company’s unaudited pro forma revenue and net loss for the quarters ended September 30, 2017 and 2016 and for the nine months ended September 30, 2017 and 2016 below have been prepared as if Best Doctors and HealthiestYou had been purchased on January 1, 2016.

Unaudited Pro Forma

Unaudited Pro Forma

Quarters Ended

Nine Months Ended

September 30,

September 30,

(in thousands)

2017

2016

2017

2016

Revenue

$
72,562

$
56,106

$
217,506

$
163,718

Net loss

$
(31,281)

$
(33,278)

$
(65,532)

$
(74,889)

The unaudited pro forma financial information above is not necessarily indicative of what the Company’s consolidated results actually would have been if the acquisitions had been completed at the beginning of the respective periods. In addition, the unaudited pro forma information above does not attempt to project the Company’s future results.

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

Note 4.5. Intangible Assets, Net

Intangible assets, net consist of the following (in thousands):


								Weighted
								Average
	Useful			Accumulated		Net Carrying		Remaining
	Life	Gross Value		Amortization		Value		Useful Life
September 30, 2017

																Weighted
																Average
									Useful			Accumulated		Net Carrying		Remaining
									Life	Gross Value		Amortization		Value		Useful Life
March 31, 2020
Client relationships									2 to 20 years	$	232,987	$	(65,733)	$	167,254	13.0
Non-compete agreements									1.5 to 5 years		4,930		(4,366)		564	1.2
Trademarks									3 to 15 years		41,764		(7,727)		34,037	12.6
Patents									3 years		200		(200)		0	0
Internal-use software and other									3 to 5 years		37,219		(24,408)		12,811	2.4
Intangible assets, net										$	317,100	$	(102,434)	$	214,666	12.3
December 31, 2019
Client relationships	2 to 10 years	$	136,368	$	(11,326)	$	125,042	9.5	2 to 20 years	$	237,182	$	(60,647)	$	176,535	13.1
Non-compete agreements	1.5 to 5 years		3,480		(2,943)		537	0.9	1.5 to 5 years		4,958		(4,260)		698	1.4
Trademarks	3 to 15 years		26,456		(960)		25,496	14.4	3 to 15 years		42,606		(7,143)		35,463	12.9
Patents	3 years		200		(55)		145	2.2	3 years		200		(200)		0	0
Internal-use software	3 to 5 years		18,974		(5,624)		13,350	1.9	3 to 5 years		34,850		(22,093)		12,757	2.3
Intangible assets, net		$	185,478	$	(20,908)	$	164,570	9.6		$	319,796	$	(94,343)	$	225,453	12.4
December 31, 2016
Client relationships	2 to 10 years	$	22,581	$	(6,226)	$	16,355	8.5
Non-compete agreements	1.5 to 5 years		3,480		(2,344)		1,136	1.6
Trademarks	3 years		1,320		(287)		1,033	2.4
Patents	3 years		200		(6)		194	2.9
Internal-use software	3 to 5 years		8,976		(2,819)		6,157	3.0
Intangible assets, net		$	36,557	$	(11,682)	$	24,875	6.5

Amortization expense for intangible assets was ~~$5.3~~$8.9 million and ~~$2.0~~$8.7 million for the quarters ended ~~September 30, 2017~~March 31, 2020 and ~~2016, respectively and $9.2 million and $4.1 million for the nine months ended September 30, 2017 and 2016,~~2019, respectively.

Note 5.6. Goodwill

Goodwill consists of the following (in thousands):


	As of September 30,		As of December 31,
	2017		2016

					As of March 31,
					2020
Beginning balance	$	188,184	$	56,342	$	746,079
Additions associated with acquisitions		307,517		131,842
Cumulative translation adjustment		2,848		-		(11,693)
Goodwill	$	498,549	$	188,184	$	734,386

Note 7. Leases

The Company commenced a new 5 year lease on March 1, 2020 for office space in Santa Clara, CA. As a result the Company recorded a right-of-use asset and lease liability of $6.8 million as of March 1, 2020.

Table of Contents

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

Note 6.8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

As of September 30,

As of December 31,


2017

2016

Professional fees

$
1,520

$
293

Consulting fees/provider fees

3,233

1,687

Client performance guarantees

2,421

431

Legal fees

607

897

Interest payable

2,849

389

Marketing

2,149

142

Earnout and compensation

2,543

1,045

Printing and postage

844

—

Deferred revenue

3,522

1,002

Other

4,449

2,095

Total

$
24,137

$
7,981


	As of March 31,		As of December 31,
	2020		2019
Professional fees	$	1,567	$	1,535
Consulting fees/provider fees		16,668		10,618
Client performance guarantees		3,087		3,298
Legal fees		1,549		1,077
Interest payable		3,889		838
Income tax payable		5,478		2,859
Insurance		1,587		1,263
Marketing		3,052		2,810
Operating lease liabilities - current		5,836		5,088
Deferred revenue		17,872		12,466
Other		11,342		7,996
Total	$	71,927	$	49,848

Note 7.9. Fair Value Measurements

The Company measures its financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires it to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active

markets.

Level 2—Include other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs that are supported by little or no market activity.

The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets and quoted prices directly in active markets.

The Company measures its short-term ~~marketable securities~~investments at fair value on a recurring basis and classifies such as Level 2. They are valued using observable inputs that reflect quoted prices directly or indirectly in active markets. The short-term ~~marketable securities~~investments amortized cost approximates fair value.

The Company ~~measures~~measured its contingent consideration at fair value on a recurring basis and ~~classifies~~classified such as Level 3. The Company estimates the fair value of contingent consideration as the present value of the expected contingent payments, determined using the weighted probability of the possible payments.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis using the above input categories (in thousands):

September 30, 2017


Level 1

Level 2

Level 3

Total
Cash and cash equivalents

$
68,137

$
14,982

$
—

$
83,119
Short-term marketable securities

$
—

$
89,758

$
—

$
89,758
Contingent liability (included in other liabilities)

$
—

$
—

$
3,991

$
3,991


	March 31, 2020
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	507,956	$	0	$	0	$	507,956
Short-term investments	$	0	$	2,819	$	0	$	2,819
Contingent liability	$	0	$	0	$	4,782	$	4,782

Table of Contents

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

December 31, 2016


Level 1

Level 2

Level 3

Total
Cash and cash equivalents

$
50,015

$
—

$
—

$
50,015
Short-term marketable securities

$
—

$
15,793

$
—

$
15,793
Contingent liability (included in accrued expenses and other current liabilities and other liabilities)

$
—

$
—

$
3,678

$
3,678


	December 31, 2019
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	514,353	$	0	$	0	$	514,353
Short-term investments	$	0	$	2,711	$	0	$	2,711
Contingent liability	$	0	$	—	$	4,769	$	4,769

There were no transfers between fair value measurement levels during the quarter ended March 31, 2020 and ~~nine months ended September 30, 2017 and 2016.~~2019.

The change in fair value of the Company’s contingent liability is recorded in general and administrative expenses in the consolidated statements of operations. The following table reconciles the beginning and ending balance of the Company’s Level 3 contingent liability:

Balance at December 31, 2016

$
3,678
Change in fair value

313
Fair value at September 30, 2017

$
3,991


Fair value at December 31, 2019	$	4,769
Payments		0
Change in fair value		105
Currency translation adjustment		(92)
Fair value at March 31, 2020	$	4,782

Note ~~8. Long Term Bank and Other Debt~~10. Revolving Credit Facility

~~Long‑term bank and other debt consist of the following (in thousands):~~

As of September 30,

As of December 31,


2017

2016

Senior Secured Term Loan, less debt discount of $8,062

$
166,938

$
—

SVB Mezzanine Term Loan

—

25,000

SVB Line of Credit Facility less debt discount of $66

—

17,424

Subordinated Promissory Note

—

2,000

Total

166,938

44,424

Less: current portion of Subordinated Promissory Note

—

(2,000)

Long term bank and other debt

$
166,938

$
42,424

~~Long term bank and other debt are stated at amortized cost, which approximates fair value.~~

~~On July 14, 2017 and concurrent with the consummation of the Best Doctors acquisition, the~~The Company entered into ~~a $175.0 million Senior Secured Term Loan Facility (the “New Term Loan Facility”) and~~ a $10.0 million Senior Secured Revolving Credit Facility (the “New Revolving Credit Facility” ~~and together with the New Term Loan Facility, the “New Senior Secured Credit Facilities”~~) ~~pursuant to a credit agreement by and among the Company, the lenders party thereto from time to time and Jefferies Finance LLC, as administrative agent and collateral agent.~~in 2017. The ~~New Term Loan Facility has been used to fund the expansion of the Company’s business and the~~ New Revolving Credit Facility is available for working capital and other general corporate purposes.

The New Term Loan Facility carries interest at a rate of 7.25% above fixed 90 days Libor of 1.24% (or 8.49%) and matures in July 2022. Interest payments are payable monthly in arrears. The New Revolving Credit Facility carries interest at a rate of 7.25% above fixed 90- days Libor of 1.24% and matures in July 2020. The Company ~~is also required to pay a commitment fee on the average daily unused portion of~~has maintained the New Revolving Credit Facility ~~at 0.50%. The Company incurred expenses of $8.3 million in conjunction with obtaining the New Senior Secured Credit Facilities.~~

~~In July 2016, the Company entered into an Amended~~ and, Restated Loan and Security Agreement with Silicon Valley Bank (“SVB”), that provided for a $25 million Mezzanine Term Loan and a $25 million Line of Credit Facility. The Mezzanine Term Loan carried interest at a rate of 6.25% above the Wall Street Journal (“WSJ”) Prime Rate with a WSJ Prime Rate floor of 3.75% and matured in July 2019. Interest payments were payable monthly in arrears. The Company incurred a $250,000 loan origination fee and was liable for a final payment fee of $750,000 payable at maturity or upon prepayment of the Mezzanine Term Loan. In connection with entry into the Mezzanine Term Loan, the

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

Company granted two affiliates of SVB warrants to purchase an aggregate of 798,694 shares of common stock of the Company at an exercise price of $13.50 per share. The warrants were immediately exercisable and had a 10-year term. The fair value of the common stock warrants on the date of issue was approximately $7.7 million. The Company also granted SVB a security interest in significantly all of the Company’s assets. The Mezzanine Term Loan had been used to fund the expansion of the Company’s business.

~~The amended Line of Credit Facility provided for borrowings up to $25 million based on 300% of the Company’s monthly recurring revenue, as defined. In addition,~~ there was ~~an additional $25 million Uncommitted Incremental Facility permitted under the Line~~0 amount outstanding as of ~~Credit Facility. The Line of Credit Facility carried interest at a rate of 0.50% above the WSJ Prime Rate~~March 31, 2020 and ~~matured in July~~December 31, 2019. The Company ~~incurred an initial $75,000 loan origination fee and is responsible~~utilized $2.2 million of letters of credit for additional $75,000 in annual fees on the anniversary of the Line of Credit Facility. The Company was also liable for a $50,000 loan arrangement fee if and when the Company utilized the Uncommitted Incremental Facility.

On July 13, 2017, the Company repaid and extinguished all the outstanding amounts under both of the SVB Line of Credit Facility and Mezzanine Term Loan of $17.5 million and $25 million, respectively, including early termination and final deferred origination fees of $1.7 million and recorded a one-time charge reflected on the consolidated statements of operations as amortization of warrants and loss on extinguishment of debt.

Effective with the purchase of AmeriDoc, LLC (“AmeriDoc”) in 2014, the Company executed a Subordinated Promissory Note in the amount of $3.5 million payable to the seller of AmeriDoc on April 30, 2015. The Subordinated Promissory Note carried interestfacility security deposits at ~~a rate of 10.00% annual interest and is subordinated to the SVB Facilities. In~~ March 2015, the Company, the seller of AmeriDoc and SVB executed an Amended and Restated Subordinated Promissory Note that extended the maturity of the Amended and Restated Subordinated Promissory Note to April 30, 2017. In November 2015, the Company executed the Second Amended and Restated Subordinated Promissory Note with a revised annual interest rate of 7% commencing on January 1, 2016 and extended the maturity of the Second Amended and Restated Subordinated Promissory Note to April 30, 2018 with a seller put option effective on April 30, 2017. The Company repaid $1.0 million during 2016 and the remaining outstanding amount of $2.0 million was paid during the first quarter of 2017.31, 2020.

The Company was in compliance with all debt covenants at ~~September 30, 2017~~March 31, 2020 and December 31, ~~2016.~~2019.

Note 9.11. Convertible Senior Notes

Convertible Senior Notes Due 2025

On May 8, 2018, the Company issued, at par value, $287.5 million aggregate principal amount of 1.375% convertible senior notes due 2025. The 2025 Notes bear cash interest at a rate of 1.375% per year, payable semi-annually in arrears on May 15 and November 15 of each year. The 2025 Notes will mature on May 15, 2025. The net proceeds to the Company from the offering were $279.1 million after deducting offering costs of approximately $8.4 million.

The 2025 Notes are senior unsecured obligations of the Company and rank senior in right of payment to the Company’s indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to the Company’s liabilities that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities incurred by the Company’s subsidiaries.

Holders may convert all or any portion of their 2025 Notes in integral multiples of $1,000 principal amount, at their option, at any time prior to the close of business on the business day immediately preceding November 15, 2024 only under the following circumstances:

●

during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the shares of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

●

during the 5 business day period after any 10 consecutive trading day period in which the trading price was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;

●

upon the occurrence of specified corporate events described under the 2025 Notes Indenture; or

Table of Contents

●

if the Company calls the 2025 Notes for redemption, at any time until the close of business on the second business day immediately preceding the redemption date.

On or after November 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2025 Notes, regardless of the foregoing circumstances.

The conversion rate for the 2025 Notes was initially, and remains, 18.6621 shares of the Company’s common stock per $1,000 principal amount of the 2025 Notes, which is equivalent to an initial conversion price of approximately $53.58 per share of the Company’s common stock. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. If the Company elects to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of the Company’s common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 25 trading day observation period.

The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after May 22, 2022 if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including the trading day immediately preceding the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any 2025 Note for redemption on or after May 22, 2022 will constitute a make-whole fundamental change with respect to that 2025 Note, in which case the conversion rate applicable to the conversion of that Note, if it is converted in connection with the redemption, will be increased in certain circumstances as described in the 2025 Notes Indenture.

In accounting for the issuance of the 2025 Notes, the Company separated the 2025 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2025 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense from the issuance date to November 15, 2024 (the first date on which the Company may be required to repurchase the 2025 Notes at the option of the holder). The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component related to the 2025 Notes was $91.4 million, net of issuance costs which was recorded in additional paid-in capital on the accompanying consolidated balance sheet.

In accounting for the transaction costs related to the issuance of the 2025 Notes, the Company allocated the total costs incurred to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are being amortized to interest expense over the seven-year term of the 2025 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders’ equity.

The 2025 Notes consist of the following (in thousands):


	As of March 31,		As of December 31,
Liability component	2020		2019
Principal	$	287,500	$	287,500
Less: Debt discount, net (1)		(78,131)		(81,207)
Net carrying amount	$	209,369	$	206,293

(1)

Included in the accompanying consolidated balance sheets within convertible senior notes and amortized to interest expense over the expected life of the 2025 Notes using the effective interest rate method.

The fair value of the 2025 Notes was approximately $833.8 million as of March 31, 2020. The Company estimates the fair value of its 2025 Notes utilizing market quotations for debt that have quoted prices in active markets. Since the 2025 Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities, which are classified as Level 2 measurements within the fair value hierarchy. See Note 9, “Fair Value Measurements,” for

Table of Contents

definitions of hierarchy levels. As of March 31, 2020, the remaining contractual life of the 2025 Notes is approximately 5.1 years.

The following table sets forth total interest expense recognized related to the 2025 Notes (in thousands):


	Quarters Ended
	March 31,
	2020			2019
Contractual interest expense	$	988		$	975
Amortization of debt discount		3,076			2,836
Total	$	4,064		$	3,811
Effective interest rate of the liability component		7.9	%		7.9	%

Convertible Senior Notes Due 2022

On June 27, 2017, the Company issued, at par value, $275 million aggregate principal amount of 3% convertible senior notes due ~~2022 (the “2022 Notes”).~~2022. The 2022 Notes bear cash interest at a rate of 3% per year, payable semi-annually in arrears on June 15 and December 15 of each ~~year, beginning on December 15, 2017.~~year. The 2022 Notes will mature on December 15, 2022. The net proceeds to the Company from the offering were $263.7 million after deducting offering costs of approximately $11.3 million.

The 2022 Notes are senior unsecured obligations of the Company and rank senior in right of payment to the Company’s indebtedness that is expressly subordinated in right of payment to the 2022 Notes; equal in right of payment to the Company’s liabilities that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities incurred by the Company’s subsidiaries.

Holders may convert all or any portion of their 2022 Notes in integral multiples of $1,000 principal amount, at their option, at any time prior to the close of business on the business day immediately preceding June 15, 2022 only under the following circumstances:

●

upon the occurrence of specified corporate events described under the 2022 Notes Indenture; or

●

if the Company calls the 2022 Notes for redemption, at any time until the close of business on the second business day immediately preceding the redemption date.

•during any calendar quarter commencing after the calendar quarter ending on September 30, 2017 (and only during such calendar quarter), if the last reported sale price of the shares of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

•during the five business day period after any ten consecutive trading day period (the ‘‘measurement period’’) in which the trading price (as defined in the 2022 Notes Indenture) per $1,000 principal amount of 2022 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;

~~•upon the occurrence of specified corporate events described under the 2022 Notes Indenture; or~~

•if the Company calls the 2022 Notes for redemption, at any time until the close of business on the second business day immediately preceding the redemption date as described under the 2022 Notes Indenture.

•On or after June 15, 2022, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2022 Notes, ~~in integral multiples of $1,000 principal amount, at the option of the holder~~ regardless of the foregoing circumstances.

The conversion rate for the 2022 Notes was initially, and remains, 22.7247 shares of the Company’s common stock per $1,000 principal amount of the 2022 Notes, which is equivalent to an initial conversion price of approximately $44.00 per share of the Company’s common stock. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. If the Company elects ~~(or are deemed to have elected)~~ to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of the Company’s common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 25 trading day observation ~~period (as defined in the 2022 Notes Indenture).~~period.

Table of Contents

20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including the trading day immediately preceding the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the 2022 Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any 2022 Note for redemption on or after December 22, 2020 will constitute a make-whole fundamental change with respect to that 2022 Note, in which case the conversion rate applicable to the conversion of that Note, if it is converted in connection with the redemption, will be increased in certain circumstances as described in the 2022 Notes Indenture.

In accounting for the issuance of the 2022 Notes, the Company separated the 2022 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2022 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense from the issuance date to June 15, 2022 (the first date on which the Company may be required to repurchase the 2022 Notes at the option of the holder). The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component related to the 2022 Notes was $62.4 million, net of issuance costs which was recorded in additional paid-in capital on the accompanying condensed consolidated balance sheet.

In accounting for the transaction costs related to the issuance of the 2022 Notes, the Company allocated the total costs incurred to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are being amortized to interest expense over the five and a half year term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders’ equity.

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

The 2022 Notes consist of the following (in thousands):


	As of March 31,		As of December 31,
Liability component	2020		2019
Principal	$	274,970	$	274,995
Less: Debt discount, net (2)		(37,118)		(40,878)
Net carrying amount	$	237,852	$	234,117

As of September 30,
Liability component

2017
Principal

$
275,000
Less: Debt issuance costs, net (1)

(70,607)
Net carrying amount

$
204,393

~~(1)~~

(2)

Included in the accompanying consolidated balance sheets within convertible senior notes and amortized to interest expense over the expected life of the 2022 Notes using the effective interest rate method.

The fair value of the 2022 Notes was approximately ~~$298~~$970.2 million as of ~~September 30, 2017.~~March 31, 2020. The Company estimates the fair value of its 2022 Notes utilizing market quotations for debt that have quoted prices in active markets. Since the 2022 Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities, which are classified as Level 2 measurements within the fair value hierarchy. See Note 7,9, “Fair Value Measurements,” for definitions of hierarchy levels. As of ~~September 30, 2017,~~March 31, 2020, the remaining contractual life of the 2022 Notes is approximately ~~4.8~~2.7 years.

The following table sets forth total interest expense recognized related to the 2022 Notes (in thousands):


	Nine Months Ended September 30,
	2017

				Quarters Ended
					March 31,
				2020			2019
Contractual interest expense	$	2,147		$	2,062		$	2,034
Amortization of debt discount		3,075			3,761			3,374
Total	$	5,222		$	5,823		$	5,408
Effective interest rate of the liability component		10.0	%		10.0	%		10.0	%

Table of Contents

Note ~~10. Commitments and Contingencies~~

12. Legal Matters

From time to time, Teladoc Health is involved in various litigation matters arising out of the normal course of business, including the matters described below. The Company consults with legal counsel on those issues related to litigation and seek input from other experts and advisors with respect to such matters. Estimating the probable losses or a range of probable losses resulting from litigation, government actions and other legal proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, may ~~become~~involve discretionary amounts, present novel legal theories, are in the early stages of the proceedings, or are subject to ~~legal proceedings, claims~~appeal. Whether any losses, damages or remedies ultimately resulting from such matters could reasonably have a material effect on our business, financial condition, results of operations, or cash flows will depend on a number of variables, including, for example, the timing and amount of such losses or damages (if any) and the structure and type of any such remedies. Teladoc Health’s management does not presently expect any litigation ~~arising in the ordinary course~~matter to have a material adverse impact on our business, financial condition, results of ~~its business. At September 30, 2017, the Company~~operations or cash flows.

On December 12, 2018, a purported securities class action complaint (Reiner v. Teladoc Health, Inc., et.al.) was ~~party to the following legal proceedings:~~

~~On April 29, 2015, the Company~~ filed ~~a lawsuit against the Texas Medical Board (the ‘‘TMB’’)~~ in the United States District Court for the ~~Western~~Southern District of ~~Texas, Austin Division~~New York (the ~~“District Court”~~“SDNY”) ~~alleging~~against the Company and certain of the Company’s officers and a former officer. The complaint is brought on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period March 3, 2016 through December 5, 2019. The complaint asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegedly false or misleading statements and omissions with respect to, among other things, the alleged misconduct of one of the Company’s previous Executive Officers. The complaint seeks certification as a class action and unspecified compensatory damages plus interest and attorneys’ fees. The Company believes that the ~~TMB’s adoption on April 10, 2015 of an amendment~~claims against the Company and its officers are without merit, and the Company and its named officers intend to ~~22 T.A.C. 190.8(1)(L) that would require a prior in-person examination for a doctor validly to prescribe any controlled substance to a patient in Texas constitutes a violation,~~ ~~inter alia, of~~defend the Sherman Antitrust Act. The District Court held a hearing on May 22, 2015 on Teladoc’s motion for preliminary injunction of the effectiveness of such amendment, which otherwise was scheduled to take effect on June 3, 2015. On May 29, 2015, the District Court issued the preliminary injunction requested by Teladoc and enjoined the effectiveness of such rule amendment pending trial. On July 30, 2015, the TMB filedCompany vigorously, including filing a motion to dismiss the ~~suit,~~complaint.

In addition, on June 21, 2019, a stockholder derivative lawsuit (Kreutter v. Gorevic, et al.) was filed in the SDNY against certain current and former directors and officers of the Company. The derivative lawsuit alleges that the named directors and officers breached their fiduciary duties to the Company in connection with factual assertions substantially similar to those in the purported securities class action complaint described above. The Company believes that the claims set forth in this stockholder derivative lawsuit are without merit.

On May 14, 2018, a purported class action complaint (Thomas v. Best Doctors, Inc.) was filed in the United States District Court for the District ~~Court denied this motion~~of Massachusetts against the Company’s wholly owned subsidiary, Best Doctors, Inc. The complaint alleges that on ~~December 14, 2015. On January 8, 2016, the TMB provided notice of its intent to appeal the District Court’s denial of its motion to dismiss to~~or about May 16, 2017, Best Doctors violated the U.S. ~~Court of Appeals~~Telephone Consumer Protection Act (TCPA) by sending unsolicited facsimiles to plaintiff and certain other recipients without the recipients’ prior express invitation or permission. The lawsuit seeks statutory damages for each violation, subject to trebling under the ~~Fifth Circuit, which was filed on June 17, 2016~~TCPA, and voluntarily withdrawn by the TMB on October 17, 2016. On November 2, 2016, the District Court granted the parties’ joint motion to stay the trial case through April 19, 2017. On April 10, 2017, the District Court granted the parties’ joint motion to stay the trial case through September 1, 2017. On September 7, 2017, the District Court granted the parties’ joint motion to stay the trial case through November 30, 2017. Accordingly, no trial date has been set.

Business in the State of Texas accounted for approximately $12.4 million, or 8% and $15.1 million or 12% of the Company’s consolidated revenue for the nine months ended September 30, 2017 and for the year ended December 31, 2016, respectively. If the TMB’s proposed rule amendments go into effect as written and Teladoc is unable to adapt its business model in compliance with the revised rules, its ability to operate its business in the State of Texas could be

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~materially adversely affected, which would have a material adverse effect on its business, financial condition and results of operations.~~

Other than as stated the Company is not a party to any material legal proceeding, and it is not aware of any pending or threatened litigation that would have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably.

injunctive relief. The Company ~~routinely assesses all of its litigation~~will vigorously defend the lawsuit and ~~threatened litigation as~~any potential loss is currently deemed to the probability of ultimately incurring a liability and records its best estimate of the ultimate loss in situations where it assesses the likelihood of loss as probable and estimable. In this regard, the Company establishes accruals for various lawsuits, claims, investigations and proceedings when it is probable that an asset has been impaired or a liability incurred at the date of the financial statements and the loss can be reasonably estimated. At September 30, 2017, the Company has established accruals for certain of its lawsuits, claims, investigations and proceedings based upon estimates of the most likely outcome in a range of loss or the minimum amounts in a range of loss if no amount within a range is a more likely estimate. The Company does not believe that at September 30, 2017 any reasonably possible losses in excess of the amounts accrued would be material to the unaudited consolidated financial statements.immaterial.

Note ~~11.~~13. Common Stock and Stockholders’ Equity

Capitalization

~~On January 24, 2017, Teladoc closed on its Follow-On Offering in which~~Effective May 31, 2018, the ~~Company issued and sold 7,887,500~~authorized number of shares of the Company’s common stock ~~including the exercise of an underwriter option~~was increased from 100,000,000 to purchase additional shares, at an issuance price of $16.75 per share. The Company received net proceeds of $123.9 million after deducting underwriting discounts and commissions of $7.6 million as well as other offering expenses of $0.6 million. 150,000,000 shares.

~~Warrants~~

In July 2016, in conjunction with the debt refinancing of the Mezzanine Term Loan, the Company issued 798,694 common stock warrants to purchase an aggregate of 798,694 shares of its common stock at an exercise price of $13.50 per share to two entities affiliated with SVB. The common stock warrants were immediately exercisable upon issuance and had a 10-year term. The fair value of the common stock warrants on the date of issue was approximately $7.7 million.

On December 9, 2016, the Company issued an aggregate of 107,931 shares of common stock resulting from an SVB affiliate’s cashless exercise of 399,347 of these warrants at an exercise price of $13.50 per share.

On January 31, 2017, the Company issued an aggregate of 138,903 shares of common stock resulting from an SVB affiliate’s cashless exercise of the remaining 399,347 of these warrants at an exercise price of $13.50 per share.

~~The Company had no warrants outstanding as of September 30, 2017 and 399,347 warrants outstanding as of December 31, 2016.~~

Stock Plan and Stock Options

The Company’s 2015 Incentive Award Plan and 2017 Inducement Plan (the “Plan”) provides for the issuance of incentive and non-statutory options and other equity-based awards to its employees and ~~non‑employees.~~non-employees. Options issued under the Plan are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Prior to becoming a public enterprise and pursuant to the Company’s Second Amended and Restated Stock Incentive Plan which is now retired, the Company historically issued incentive and non-statutory stock options with exercise prices equal to the fair value of the Company’s common stock on the date of grant, as determined by the Company’s board of directors informed by third-party valuations. Subsequent to becoming a public enterprise, optionsOptions to buy common stock ~~have been~~are issued under the Plan, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the ~~trading day immediately preceding the~~ date of award.

The Company had 8,161,962 shares available for grant at March 31, 2020.

Table of Contents

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

Activity under the Plan is as follows (in thousands, except share and per share amounts and years):

Weighted-


Weighted-

Average

Shares

Number of

Average

Remaining

Aggregate

Available

Shares

Exercise

Contractual

Intrinsic

for Grant

Outstanding

Price

Life in Years

Value

Balance at December 31, 2016

343,216

6,839,868

$
11.70

8.64

$
36,795

Increase in Plan authorized shares

4,176,722

—

$
—

—

$
—

Restricted stock units granted

(342,524)

—

$
—

—

$
—

Stock option grants

(3,671,073)

3,671,073

$
25.02

—

$
—

Stock options exercised

—

(734,293)

$
9.53

—

$
14,301

Stock options forfeited

687,375

(681,759)

$
16.84

—

$
5,647

Balance at September 30, 2017

1,193,716

9,094,889

$
16.87

8.50

$
149,973

Vested or expected to vest at September 30, 2017

9,094,889

$
16.87

8.50

$
149,973

Exercisable at September 30, 2017

2,348,722

$
8.86

7.16

$
57,048


				Weighted-
		Weighted-		Average
	Number of	Average		Remaining	Aggregate
	Shares	Exercise		Contractual	Intrinsic
	Outstanding	Price		Life in Years	Value
Balance at December 31, 2019	5,206,981	$	24.47	7.03	$	308,538
Stock option grants	7,441	$	106.25	0	$	0
Stock options exercised	(671,279)	$	22.10	0	$	(65,192)
Stock options forfeited	(126,577)	$	34.48	0	$	0
Balance at March 31, 2020	4,416,566	$	24.67	6.77	$	575,408
Vested or expected to vest at March 31, 2020	4,414,765	$	24.67	6.77	$	575,408
Exercisable at March 31, 2020	3,055,075	$	19.80	6.41	$	413,071

The total ~~grant‑date~~grant-date fair value of stock options granted during the ~~quarter~~quarters ended March 31, 2020 and ~~nine months ended September 30, 2017 were $18.5~~2019 was $0.3 million and ~~$54.8~~$1.2 million, respectively.

~~Stock‑Based~~

Stock-Based Compensation

All ~~stock‑based~~stock-based awards to employees are measured based on the ~~grant‑date~~grant-date fair value of the awards and are generally recognized on a straight line basis in the Company’s consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a ~~four‑year~~four-year vesting period for each ~~award)~~stock option and a three-year vesting period for each restricted stock unit (“RSU”). The Company estimates the fair value of stock options granted using the ~~Black‑Scholes option‑pricing~~Black-Scholes option-pricing model. ~~Compensation cost is generally recognized over the vesting period of the applicable award using the straight‑line method.~~

Given the absence of a public trading market prior to July 2015, the Company’s board of directors considered numerous objective and subjective factors to determine the fair value of its common stock at each grant date. These factors included, but were not limited to, (i) contemporaneous valuations of common stock performed by unrelated third‑party specialists; (ii) the prices for the preferred stock sold to outside investors; (iii) the rights, preferences and privileges of the preferred stock relative to the common stock; (iv) the lack of marketability of the common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an IPO or a merger or acquisition of the Company, given prevailing market conditions.

The assumptions used in the ~~Black‑Scholes option‑pricing~~Black-Scholes option-pricing model ~~were~~are determined as follows:

Volatility. Since the Company does not have a trading history prior to July 2015 for its common stock, the expected volatility was derived from the historical stock volatilities of several unrelated public companies within its industry that it considers to be comparable to its business combined with the Company’s stock volatility over a period equivalent to the expected term of the stock option grants.

~~Risk‑Free~~Risk-Free Interest Rate. The ~~risk‑free~~risk-free interest rate is based on U.S. Treasury ~~zero‑coupon~~zero-coupon issues with terms similar to the expected term on the options.

Expected Term. The expected term represents the period that the ~~stock‑based~~stock-based awards are expected to be outstanding. When establishing the expected term assumption, the Company utilizes historical data.

Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, it used an expected dividend yield of ~~zero.~~0.

Forfeiture rate. ~~Prior to 2017, the~~ The Company used historical data to estimate pre‑ vesting option forfeitures and record stock‑based compensation expense only for those awards that are expected to vest. On January 1, 2017, the Company adopted ASU 2016-09 and elected to account for stock optionrecognizes forfeitures as they ~~occur which resulted in a cumulative effect adjustment of $0.1 million recorded to accumulated deficit and additional paid-in capital.~~

occur.

Table of Contents

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

The fair value of each option grant was estimated on the date of grant using the ~~Black‑Scholes option‑pricing~~Black-Scholes option-pricing model with the following assumptions and fair value per share:

Nine Months Ended September 30,

2017

2016

Volatility

45.1% – 47.7%

44.7% – 46.3%

Expected life (in years)

6.1

6.0

Risk-free interest rate

1.81% - 2.30%

1.09% - 1.91%

Dividend yield

–

–

Weighted-average fair value of underlying common stock

$
11.83

$
6.27


	Quarters Ended March 31,
	2020		2019
Volatility		46.1% – 47.9%		47.5% – 47.6%
Expected life (in years)		4.3		5.4
Risk-free interest rate		0.87% - 1.64%		2.50% - 2.55%
Dividend yield		–		–
Weighted-average fair value of underlying stock options	$	42.06	$	27.87

For the quarter ended ~~September 30, 2017~~March 31, 2020 and ~~2016,~~2019, the Company recorded compensation expense related to stock options granted of ~~$5.0~~$3.9 million and ~~$2.2~~$5.5 million, ~~respectively, and $12.2 million and $5.1 million for the nine months ended September 30, 2017 and 2016,~~ respectively.

As of ~~September 30, 2017,~~March 31, 2020, the Company had ~~$55.8~~$20.0 million in unrecognized compensation cost related to ~~non‑vested~~non-vested stock options, which is expected to be recognized over a ~~weighted‑average~~weighted-average period of approximately ~~3.1~~1.8 years.

Restricted Stock Units

In May 2017, the Company commenced issuing ~~Restricted Stock Units (“RSU’s”)~~RSUs pursuant to the Plan to certain employees and Board members under the 2017 Employment Inducement Incentive Award Plan.

The fair value of the ~~RSU’s~~RSUs is determined on the date of grant. ~~On a monthly basis, the~~The Company will record compensation expense in the consolidated statement of operations on a straight-line basis over the vesting ~~period.~~period for RSUs. The vesting period for employees and members of the Board of Directors isranges from one to four ~~years and one year, respectively.~~years.

Activity under the ~~RSU’s~~RSUs is as ~~follows (in thousands, except share and per share amounts and years):~~follows:


		Weighted-Average
		Grant Date
	Shares	Fair Value Per Share
Balance at December 31, 2019	1,483,558	$	54.13
Granted	321,311	$	122.96
Vested and issued	(455,956)	$	51.79
Forfeited	(54,476)	$	48.78
Balance at March 31, 2020	1,294,437	$	58.82
Vested and unissued at March 31, 2020	13,755	$	50.90
Non-vested at March 31, 2020	1,280,682	$	58.91

Weighted-Average

Grant Date

Shares

Fair Value Per Share
Balance at December 31, 2016

—

$
—
Granted

342,524

$
33.19
Cancelled/Forfeited

(5,616)

$
30.50
Balance at September 30, 2017

336,908

$
33.23
Vested and deferred at September 30, 2017

—

$
—
Non-vested at September 30, 2017

336,908

$
33.23

The total ~~grant‑date~~grant-date fair value of ~~RSU’s~~RSUs granted during the quarter ended March 31, 2020 and ~~nine months ended September 30, 2017~~2019 were ~~$6.9~~$39.5 million and ~~$11.3~~$48.0 million, respectively.

For ~~both of~~ the quarter ended March 31, 2020 and ~~nine months ended September 30, 2017,~~2019, the Company recorded ~~stock based~~stock-based compensation expense related to the ~~RSU’s~~RSUs of ~~$0.8~~$9.4 million and ~~$0.9~~$5.0 million respectively. ~~There was no charge~~

As of March 31, 2020, the Company had $82.8 million in unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted-average period of approximately 2.0 years.

Performance Stock Units

The Company began issuing grants Performance Stock Units (“PSUs”) to employees under the Plan in 2018. Stock-based compensation costs associated with our PSUs are initially determined using the fair market value of the Company's common stock on the date the awards are approved by the Compensation Committee of the Board of Directors (service inception date). The vesting of these PSU is subject to certain performance conditions and a service requirement ranging from 1-3 years. Until the performance conditions are met, stock compensation costs associated with these PSU reflect the estimated performance attainment on the reporting date. The ultimate number of PSUs that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance conditions and can range from 50% to 200% of the initial grant. Stock compensation expense for PSUs is recognized on an accelerated tranche by tranche basis for performance-based awards. Forfeitures are accounted for at the time the occur consistent with Company policy.

Table of Contents

Activity under the PSU is as follows:


		Weighted-Average
		Grant Date
	Shares	Fair Value Per Share
Balance at December 31, 2019	512,482	$	62.51
Granted	111,199	$	117.81
Vested and issued	(186,455)	$	62.02
Balance at March 31, 2020	437,226	$	76.78
Vested and unissued at March 31, 2020	0	$	0
Non-vested at March 31, 2020	437,226	$	76.78

The total grant-date fair value of PSUs granted during the quarter ended March 31, 2020 and ~~nine months~~2019 were $13.1 million and $28.4 million, respectively.

For the quarter ended ~~September 30, 2016.~~March 31, 2020 and 2019, the Company recorded stock-based compensation expense related to the PSU of $4.6 million and $2.6 million, respectively.

As of March 31, 2020, the Company had $25.4 million in unrecognized compensation cost related to non-vested PSU, which is expected to be recognized over a weighted-average period of approximately 1.8 years.

Employee Stock Purchase Plan

In July 2015, the Company adopted the 2015 Employee Stock Purchase Plan, or ESPP, in connection with its initial public offering. A total of ~~551,641~~832,492 shares of common stock were reserved for issuance under this plan as of ~~September 30, 2017.~~March 31, 2020. The Company’s ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Under the ESPP, the Company may specify offerings with durations of not more than 27 months and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of its common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. The price at which the stock is purchased is equal

~~Table of Contents~~

~~TELADOC, INC.~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or on the date of purchase.

~~On May 8, 2017,~~During the ~~Company issued 90,968 shares under the ESPP and~~quarter March 31, 2020, the Company had not issued any shares under the ~~ESPP as~~ESPP. During 2019, the Company issued 64,497 shares under the ESPP. As of ~~December~~March 31, ~~2016. 460,673~~2020, 555,267 shares remained available for ~~issuance as of September 30, 2017.~~issuance.

For the quarter ended ~~September 30, 2017~~March 31, 2020 and ~~2016,~~2019, the Company recorded stock-based compensation expense related to the ESPP of $0.4 million and $0.3 million, respectively.

As of March 31, 2020, the Company had $0.2 million ~~and $0.1 million, respectively. For the nine months ended September 30, 2017 and 2016, the Company recorded stock-based~~in unrecognized compensation ~~expense~~cost related to the ESPP, which is expected to be recognized over a weighted-average period of ~~$0.5 million and $0.1 million, respectively, based on offerings made under the plan to-date.~~approximately 0.1 years.

Total compensation costs charged as an expense for ~~stock‑based~~stock-based awards, including stock options, RSU’s and ESPP, recognized in the components of operating expenses are as follows (in thousands):


	Quarters Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016

									Quarter Ended
									March 31,
									2020		2019
Administrative and marketing	$	315	$	132	$	798	$	348	$	1,259	$	821
Sales		1,293		355		2,894		794		2,919		2,130
Technology and development		852		322		2,048		797		2,104		1,898
General and administrative		3,506		1,356		7,888		3,148		12,033		8,674
Total stock-based compensation expense	$	5,966	$	2,165	$	13,628	$	5,087	$	18,315	$	13,523

Note ~~12.~~14. Income Taxes

As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its deferred tax assets for assets that are not more-likely-than-not to be realized. For the quarter ended March 31, 2020, the Company recognized an income tax benefit of $0.7 million, primarily due to the

Table of Contents

amortization of acquired intangibles and ~~nine months~~stock compensation deductions. For the quarter ended ~~September 30, 2017,~~March 31, 2019, the income tax ~~provision~~expense was ~~recognized~~primarily due U.S. tax expense for ~~timing differences with respect~~its non-consolidated U.S. subsidiary, which was transferred to the ~~treatment~~U.S. parent company in the fourth quarter of 2019 and as a result the ~~amortization of tax deductible goodwill~~subsidiary’s 2020 income will be offset by other U.S. losses as the company has elected to include it in the U.S. consolidation, as well as ~~foreign related income partially offset by a tax benefit associated~~amortization of tax-deductible goodwill.

Beginning with ~~the expiration of a statute of limitations. Income tax provisions recognized for~~ the quarter ended March 31, 2018, the Company is calculating tax expense based on the U.S. statutory rate of 21%. The US Federal tax law includes a Base Erosion Anti-Abuse Tax, commonly referred to as BEAT, which imposes a minimum tax on certain deductible payments or accruals made to foreign affiliates in tax years beginning after December 31, 2017. The Company has determined that it is currently not subject to BEAT. US Federal tax law imposes a minimum tax on global intangible low-taxed income, commonly referred to as GILTI. The Company does not expect to recognize any tax expense related to GILTI as it has net operating losses available and ~~nine months ended September 30, 2016, were primarily attributable~~a full valuation allowance. In addition, US Tax law imposes an interest expense limitation which disallows a portion of the interest deduction based on EBITDA. While the disallowed interest deduction is deferred, there is no impact to tax expense due to the ~~timing differences with respect to the treatment of the amortization of tax deductible goodwill. A majority of the Company’s operations,~~current year taxable loss and ~~resulting deferred tax assets, were generated in the United States.~~related valuation allowance.

1920

Table of Contents

~~Item~~2.

Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements other than statements of historical fact are, or may be, forward-looking statements. These forward-looking statements are not historical facts, but rather are based on current expectations, estimate, assumptions and projections about our industry, business and future financial results. We use words such as “anticipates”, “believes”, “suggests”, “targets”, “projects”, “plans”, “expects”, “future”, “intends”, “estimates”, “predicts”, “potential”, “may”, “will”, “should”, “could”, “would”, “likely”, “foresee”, “forecast”, “continue” and other similar words or phrases, as well as statements in the future tense to identify these forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of important factors, including those set forth below.

●

ongoing legal challenges to or new state actions against our business model;

●

our dependence on our relationships with affiliated professional entities;

●

evolving government regulations and our ability to stay abreast of new or modified laws and regulations that currently apply or become applicable to our business;

●

our ability to operate in the heavily regulated healthcare industry;

●

our history of net losses and accumulated deficit;

●

failures of our cyber-security measures that expose the ~~impact~~confidential information of ~~recent healthcare reform legislation~~our Clients and ~~other changes in the healthcare industry;~~

Members;

●

risk of the loss of any of our significant Clients;

●

risks associated with a decrease in the number of individuals offered benefits by our Clients or the number of products and services to which they subscribe;

●

our ability to establish and maintain strategic relationships with third parties;

●

risks specifically related to our ability to operate in competitive international markets and comply with complex non-U.S. legal requirements;

●

our ability to recruit and retain a network of qualified Providers;

●

risk that the insurance we maintain may not fully cover all potential exposures;

●

rapid technological change in the telehealth market;

●

our ability to integrate acquired businesses and achieve fully the strategic and financial objectives related thereto and its impact on our financial condition and results of operations;

●

our level of indebtedness and our ability to fund debt obligations and comply with covenants in our debt instruments;

●

any statements of belief and any statements of assumptions underlying any of the foregoing;

●

other factors disclosed in this Form 10-Q; and

●

other factors beyond our control.

Table of Contents

The foregoing list of factors is not exhaustive and does not necessarily include all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. The information in this Quarterly Report should be read carefully in conjunction with other uncertainties and potential events described in our Form 10-K in the Annual Report for the year ended December 31, ~~2016~~2019 filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this Quarterly Report. Except as required by law or regulation, we do not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances.

~~Table of Contents~~

Overview

~~Overview~~

~~We are the largest and most trusted telehealth provider~~Teladoc, Inc. was incorporated in the ~~world. Recognized by MIT Technology Review~~State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2019, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. from Teladoc, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as ~~one of~~“Teladoc Health” or the ~~“50 Smartest Companies”, we are forging~~“Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in providing virtual healthcare services with a ~~new healthcare experience with better convenience, outcomes and value. We provide virtual access to~~focus on high quality, ~~care~~lower costs, and expertise, with a portfolio of services and solutions covering 450 medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. By marrying the latest in data and analytics with an award-winning user experience and a highly flexible technology platform, we have delivered millions of medical visits to patientsimproved outcomes around the ~~globe. Over 22 million unique Members now benefit from access to~~ world.

Teladoc 24 hours a day, seven days a week, 365 days a year. We completed approximately 1,000,000 telehealth visits in the first nine months of 2017 and approximately 952,000 telehealth visits for the full year of 2016. Paid membership increased by approximately 5.6 million members from September 30, 2016 through September 30, 2017 including the impact from Best Doctors.

On July 14, 2017, we completed the acquisition of Best Doctors Holdings, Inc. (“Best Doctors”), an expert medical consultation company. Best Doctors provides technology innovations and services to help employers, health plans and provider organizations to improve health outcomes for the most complex, critical and costly medical issues.

~~The Teladoc solution is~~Health solutions are transforming the access, cost and quality dynamics of healthcare delivery for all of our market participants. ~~Our~~ Members rely on Teladoc Health to remotely access affordable, on-demand healthcare whenever and wherever they choose. Employers, health plans ~~provider organization, insurance~~ and ~~financial services companies and consumers (our “Clients”)~~health systems, or our Clients, as well as our direct-to-consumer members purchase our ~~solution~~solutions to reduce their healthcare spending ~~or to provide a market differentiating service as a complement to their core set of consumer service offerings, while at the same time offering~~and offer convenient, affordable, high-quality healthcare to their employees or beneficiaries. Our network of physicians and other healthcare professionals, ~~(our “Providers”) as well as~~or our ~~medical experts~~Providers have the ability to generate meaningful income and deliver their services more efficiently with no administrative burden. We believe the value proposition of our solution is evidenced by our overall Member satisfaction rate, which has exceeded 90% over the last eight years. We further believe any consumer, employer, health plan or provider, insurance and financial service companies interested in a better approach to healthcare is a potential Teladoc Member, Client or Provider.

Revenue

We ~~generate~~have a demonstrated track record of driving growth both organically and through acquisitions. We increased revenue from our Clients on a contractually recurring, per-Member-per-month, subscription access fee basis, which provides us with significant revenue visibility. In addition, under the majority of our Client contracts, we generate additional revenue on a per-telehealth general medical visit basis, through a visit fee. Certain of our Client contracts generate revenue for expert second opinions on a per case basis. Subscription access fees are paid by our Clients on behalf of their employees, dependents, policy holders, card holders, beneficiaries or themselves, while general medical and other specialty visit fees are paid by either Clients or Members.

We generated $68.7 million, including $21.8 million from Best Doctors and $32.4 million in revenue for the quarters ended September 30, 2017 and 2016, respectively, representing 112% year-over-year growth. Excluding the impact from Best Doctors our organic growth rate was 45%. We generated $156.1 million, including $21.8 million from Best Doctors and $85.8 million in revenue for the nine months ended September 30, 2017 and 2016, respectively, representing 82% year-over-year growth. Excluding the impact from Best Doctors our organic growth rate was 57%. We had net losses of $31.3 million and $29.841% to $180.8 million for the ~~quarters~~quarter ended ~~September 30, 2017 and 2016, respectively and $62.4~~March 31, 2020, including $0.9 million ~~and $60.0 million~~from our April 2019 MedecinDirect acquisition. The increase in revenue includes an unprecedented surge in demand for our services in the ~~nine months ended September 30, 2017 and 2016, respectively.~~ month of March associated with the global outbreak of COVID-19.

For the quarter ended ~~September 30, 2017, 87%~~March 31, 2020, 76% and ~~13% of our revenue was derived from subscription access fees and visit fees, respectively and for the nine months ended September 30, 2017, 84% and 16%~~24% of our revenue was derived from subscription access fees and visit fees, respectively. For the quarter ended ~~September 30, 2016, 86% and 14% of our revenue was derived from subscription access fees and visit fees, respectively and for the nine months ended September 30, 2016,~~March 31, 2019, 82% and 18% of our revenue was derived from subscription access fees and visit fees, respectively. The increased percentage of visit related revenue in 2020 is a result of the COVID-19 pandemic. Additionally, we believe our continued strong subscription fee revenue is mainly representative of the value proposition we provide the broader U.S. healthcare system.

~~In January 2017, we successfully closed on our Follow-On Offering~~

Membership and Visits

We completed approximately 2.0 million telehealth visits in ~~which~~ the ~~Company issued~~first three months of 2020 and ~~sold 7,887,500 shares~~approximately 4.1 million telehealth visits for the full year of ~~common stock, including the exercise of an underwriter option~~2019. Paid Membership increased by approximately 6.2 million Members to ~~purchase additional shares, at an issuance price of $16.75 per share. We received net proceeds of $123.9~~43.0 million ~~after deducting underwriting discounts and commissions of $7.6 million as well as other offering expenses of $0.6 million.~~from December 31, 2019 through March 31, 2020.

~~Table of Contents~~

Acquisition History

We have scaled and intend to continue to scale our platform through the pursuit of selective acquisitions. We have completed multiple acquisitions since our inception, which we believe have expanded our distribution capabilities and broadened our service offerings.

~~On July 14, 2017, we completed our acquisition~~

Table of Best Doctors, for aggregate consideration of $445.5 million, comprised of $379.4 million of cash and $66.2 million of our common stock (or 1,855,078 shares), net of cash acquired. Best Doctors is the world’s leading expert medical consultation company focused on improving health outcomes for the most complex, critical and costly medical issues.Contents

On ~~July 1, 2016, we completed our acquisition~~January 12, 2020, the Company entered into a definitive agreement to acquire InTouch Technologies, Inc., the leading provider of ~~HY Holdings, Inc. d/b/a HealthiestYou Corporation, or HealthiestYou,~~enterprise telehealth solutions for ~~aggregate consideration~~hospitals and health systems. The transaction is expected to close by the end of ~~$151.5~~the second quarter of 2020. Under the terms of the agreement, the purchase price of $600.0 million ~~comprised~~will consist of ~~$43.2~~approximately $150.0 million ofin cash and $108.3 million of our common stock (or 6,955,796 shares), net of cash acquired. HealthiestYou is a telehealth consumer engagement technology platform for the small to mid-sized employer market. Solutions provided by HealthiestYou include 24/7 access to telephone and video conferencing with doctors as well as $450.0 million of Teladoc Health’s common stock which is subject to adjustment based on the ~~convenience~~average of ~~procedure~~the Company’s stock price ~~comparisons, prescription medicine price comparisons, health plan information and benefits eligibility and location information~~ for ~~wellness service providers.~~the ten full trading days prior to the completion of the acquisition.

On April 30, 2019, the Company completed the acquisition of the Paris-based telemedicine provider MedecinDirect in which MedecinDirect became a wholly-owned subsidiary of the Company. The aggregate merger consideration paid was $11.2 million with additional potential earnout consideration. On June 19, 2019, the Company made a $5.0 million minority investment in Vida Health which is accounted for under the cost method for investments.

Key Factors Affecting Our Performance

Number of Members. Our revenue growth rate and long-term profitability are affected by our ability to increase our number of Members because we derive a substantial portion of our revenue from subscription access fees via Client contracts that provide Members access to our professional ~~Provider~~provider network in exchange for a contractual based monthly fee. Revenue is driven primarily by the number of Clients, the number of Members in a Client’s population, the number of services contracted for by a Client and the contractually negotiated prices of our services and the negotiated pricing that is specific to that particular Client. We believe that increasing our membership is an integral objective that will provide us with the ability to continually innovate our services and support initiatives that will enhance Member experiences. Paid membershipMembership increased by approximately ~~5.6~~6.2 million ~~members~~Members to 43.0 million from ~~September 30, 2016~~December 31, 2019 through ~~September 30, 2017, including approximately 2.8 million members from the acquisition of Best Doctors.~~March 31, 2020.

Number of Visits. We also recognize revenue in connection with the completion of a general medical visit, expert ~~second opinion~~medical service and other specialty ~~visit~~visits for ~~the majority~~certain of our contracts. Accordingly, our visit revenue, or visit fees, generally increase as the number of visits increase. Visit fee revenue is driven primarily by the number of Clients, the number of Members in a Client’s population, Member utilization of our ~~Provider~~provider network services and the contractually negotiated prices of our services. We believe that increasing our current Member utilization rate and increasing penetration further ~~penetration~~ into existing and ~~sales to~~ new health plan ~~clients~~Clients is a key objective in order for our Clients to realize tangible healthcare savings with our service. Visits increased by 92% or 1.0 million to approximately ~~103,000~~2.0 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to the same period in ~~2016.~~2019. The increase in visits is reflective of our ability to secure new clients as well as the surge in demand for our services associated with COVID-19.

Seasonality. We typically experience the strongest increases in consecutive quarterly revenue during the fourth and first quarters of each year, which coincides with traditional annual benefit enrollment seasons. In particular, as a result of many Clients’ introduction of new services at the very end of the current year, or the start of each year, the majority of our new Client contracts have an effective date of January 1. ~~Additionally, as~~Therefore, while Membership increases, utilization is dampened until service delivery ramps up over the course of the year. Our business also has become more diversified across services, channels and geographies. As a result, we have seen a diversification of client start dates, resulting from our health plan expansions, cross sales of new services, international growth, and mid-market employer growth, all of which are not constrained by a calendar year start.

As a result of national seasonal cold and flu trends, we typically experience our highest level of ~~general medical~~ visit fees during the first and fourth quarters of each year when compared to other quarters of the year. Conversely, the second quarter of the year has historically been the period of lowest utilization of our ~~Provider~~provider network services relative to the other quarters of the year. We experienced a surge in demand for our services in March of 2020 associated with the COVID-19 global pandemic and anticipate that this will alter our historical seasonal utilization trends during 2020. See “Risk Factors—Risks Related to Our Business—Our quarterly results may fluctuate significantly, which could adversely impact the value of our common stock.” included in our Form 10-K for the year ended December 31, ~~2016~~2019 filed with the SEC.

~~Components of Results of Operations~~Critical Accounting Policies and Estimates

~~Revenue~~

~~We generate our revenue from our Clients who purchase access to our professional Provider network or our medical experts for their employees, dependents~~Our discussion and other beneficiaries. Our Client contracts include a per-Member-per-month subscription access fee as well as contracts that generate additional revenue on a per-telehealth visit basis for general medical and other specialty visits and expert second opinion on a per case basis. Accordingly, we generate

~~Table of Contents~~

~~subscription access revenue from our subscription access fees and visit revenue from our general medical, expert second opinion and other specialty visit fees.~~

~~Subscription access revenue accounted for approximately 87% and 86%~~analysis of our ~~total revenue during the quarters ended September 30, 2017~~results of operations, liquidity and ~~2016, respectively and 84% and 82% of~~capital resources are based on our ~~total revenue during the nine months ended September 30, 2017 and 2016, respectively. Subscription access revenue is driven primarily by the number of Clients, the number of Members~~condensed consolidated financial statements which have been prepared in a Client’s population, the number of services contracted for by a Client and the contractually negotiated prices of our services. Visit fee revenue for general medical, expert second opinion and other specialty visits is driven primarily by the number of Clients, the number of Members in a Client’s population, Member utilization of our professional Provider network services and the contractually negotiated prices of our services.

We recognize subscription access fees and visit and second opinion access fees in arrears on a monthly basis when the following criteria are met: (i) there is an executed subscription agreement, (ii) the Member has access to the service, (iii) collection of the fees is reasonably assured and (iv) the amount of fees to be paid by the Client and Member is fixed and determinable. Our agreementsconformity with accounting principles generally ~~have a term of one year. The majority of Clients renew their contracts with us following their first year of services.~~

~~Warranties and Indemnification~~

Our arrangements generally include certain provisions for indemnifying Clients against liabilities if there is a breach of a Client’s data or if our service infringes a third party’s intellectual property rights. To date, we have not incurred any material costs as a result of such indemnifications.

We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request. We maintain director and officer liability insurance coverage that would generally enable us to recover a portion of any future amounts paid. We may also be subject to indemnification obligations by law with respect to the actions of our employees under certain circumstances and in certain jurisdictions.

~~Concentrations of Risk and Significant Clients~~

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, short-term marketable securities and accounts receivable. Although we deposit our cash with multiple financial institutions in U.S. and in foreign countries, our deposits, at times, may exceed federally insured limits. Our short-term marketable securities are comprised of a portfolio of diverse high credit rating instruments with maturity durations of 1 year or less.

~~Revenue from Clients located~~accepted in the United States ~~for~~of America (“U.S. GAAP”). The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the ~~quarters ended September 30, 2017~~reported amounts of assets, liabilities, revenues and ~~2016 were $60.0 million~~expenses, and ~~$32.4 million, respectively. Revenue from Clients located in the United States for the nine months ended September 30, 2017~~disclosure of contingent assets and ~~2016 were $147.5 million~~liabilities. On an ongoing basis, we evaluate our estimates and ~~$85.8 million, respectively.~~

~~Revenue from Clients located outside the United States for the quarter and nine months ended September 30, 2017 was $8.7 million and zero in 2016.~~

~~No Client represented over 10% of revenues for the quarters and nine months ended September 30, 2017 and 2016.~~

~~No Client represented over 10% of~~judgments, including those related to revenue recognition, accounts receivable, ~~at September 30, 2017. One client represented 11% of accounts receivable at December 31, 2016.~~

~~Cost of Revenue~~

~~Cost of revenue primarily consists of fees paid to our Providers~~accounting for business combinations, goodwill, intangible assets, long-lived assets, capitalized development costs, earnout, income taxes, lease liabilities, loss contingencies and medical experts, costs incurred in connection with our Provider network operations, which include employee-related expenses (including salaries and benefits), costs related to our Provider network operations center activities, medical records, magnetic resonance imaging, medical lab tests, translation, postage and insurance, which includes coverage for medical malpractice claims.the

Table of Contents

~~Cost~~value of ~~revenue is driven primarily by the number of general medical visits, expert second opinions~~securities underlying stock-based compensation. We base our estimates on historical and anticipated results and trends and on various other specialty visits completed in each period. Many of the elements of the cost of revenue are relatively variable and semi-variable, and can be reduced in the near-term to offset any decline in our revenue. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities. While we currently expect to continue to enhance our Provider network operations center as well as our sales and technology capabilities to support business growth,assumptions that we believe ~~our increased investment in automation and integration capabilities and economies~~are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of ~~scale in our Provider network operations center operating model, will position us to grow our revenue at a greater rate than our cost of revenue.~~

~~Gross Profit~~

Our gross profit is our total revenue minus our total cost of revenue, and we also express our gross profit as a percentage of our total revenue. Our gross profit has been and will continue to be affected by a number of factors, including the fees we charge our Clients, the number of visits and cases we complete the costs paid to Providers and medical experts as well as the costs of our Provider network operations center. We expect our annual gross profit to remain relatively steady over the near term, although our quarterly gross profit is expected to fluctuate from period to period depending on the interplay of these aforementioned factors.

~~Advertising and Marketing Expenses~~

Advertising and marketing expenses consist primarily of costs of digital advertisements, personnel and related expenses for our marketing staff and communications materials that are produced to generate greater awareness and utilization among our Clients and Members. Marketing costs also include third-party independent research, trade shows and brand messages, public relations costs and stock-based compensation for our advertising and marketing employees. Our advertising and marketing expenses exclude certain allocations of occupancy expense as well as depreciation and amortization.

We expect our advertising and marketing expenses to increase for the foreseeable future as we continue to increase the size of our digital advertising and marketing operations including member engagement activities and expand into new products and markets. Our advertising and marketing expenses will fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our advertising campaigns and marketing expenses. We will continue to invest in advertising and marketing by promoting our brands through a variety of marketing and public relations activities.

~~Sales Expenses~~

Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, employment taxes, travel and stock-based compensation costs for our employees engaged in sales, account management and sales support in addition to commissions paid to external brokers. Our sales expenses exclude certain allocations of occupancy expense as well as depreciation and amortization. We expect our sales expenses to increase in the short-to-medium-term as we strategically invest to expand our business and to capture an increasing amount of our market opportunity.

~~Technology and Development Expenses~~

Technology and development expenses include personnel and related expenses for software engineering, information technology infrastructure, security and compliance and product development. Technology and development expenses also include outsourced software engineering services, the costs of operating our on-demand technology infrastructure, licensed applications and stock-based compensation for our technology and development employees. Our technology and development expenses exclude certain allocations of occupancy expense as well as depreciation and amortization.

We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development of our technology platform. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses. Historically, the majority of our technology and development costs have been expensed.

~~Table of Contents~~

~~Legal and Regulatory Expenses~~

Legal and regulatory expenses include professional fees incurred. Our legal and regulatory expenses exclude certain allocations of personnel and related expenses, occupancy expense as well as depreciation and amortization.

~~Acquisition and Integration Related Costs~~

Acquisition and integration related costs include investment banking, financing, legal, accounting, consultancy, integration and certain non-recurring transaction costs related to mergers and acquisitions.

~~General and Administrative Expenses~~

General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, product development, business development, operations and human resources departments. They also include stock-based compensation and most of the facilities costs including utilities and facilities maintenance. Our general and administrative expenses exclude any allocation of depreciation and amortization.

We expect our general and administrative expenses to increase for the foreseeable future as we continue to grow our business. However, we expect our general and administrative expenses to decrease as a percentage of our total revenue over the next several years. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.

~~Depreciation and Amortization~~

~~Depreciation and amortization consists primarily of depreciation of fixed assets, amortization of capitalized software development costs and amortization of acquisition-related intangible assets.~~

~~Amortization of Warrants and Loss on Extinguishment of Debt~~

Amortization of warrants and loss on extinguishment of debt consists of the recognition of the fair value of warrants issued in connection with the July 2016 Mezzanine Term Loan, the write-off of origination and termination financing fees and related deferred cost in connection with SVB indebtedness extinguished in connection with our July 2017 and 2016 refinancings.

~~Interest Expense, Net~~

~~Interest expense, net consists of interest costs associated with our bank and other debt, net of interest earned on short-term marketable securities.~~

~~Foreign Currency~~

~~The functional currency for each of our foreign subsidiaries is the local currency. All~~ assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the weighted average exchange rate during the period. Cumulative translation gains or losses are included in stockholders’ equity as a component of accumulated other comprehensive income (loss). We have not utilized hedging strategies with respect to such foreign exchange exposure.

~~Income Tax Provision~~

We account for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and NOLs. Deferred tax assets and liabilities are measured using the enacted tax rates that are ~~expected~~not readily apparent from other sources. By their nature, estimates are subject to ~~be in~~an inherent degree of uncertainty. Actual results may differ from our estimates and could have a significant adverse effect when the differences are expected to reverse. We assess the likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. We have also recorded deferred tax liabilities arising principally from the difference between the treatmenton our results of

~~Table of Contents~~

~~goodwill between tax~~ operations and financial position. For a discussion of our critical accounting ~~book purposes. We~~policies and estimates see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report and there have ~~provided a full valuation allowance at September 30, 2017 and December 31, 2016, due~~been no material changes to ~~the uncertainty surrounding the future realization of such assets.~~our critical accounting policies during 2020.

Consolidated Results of Operations

The following table sets forth our consolidated statement of operations data for the quarters ended March 31, 2020 and ~~nine months ended September 30, 2017 and 2016~~2019 and the dollar and percentage change between the respective periods:


	Quarters Ended September 30,								Nine Months Ended September 30,
	2017		2016						2017		2016
	$		$		Variance		%(a)		$		$		Variance		%(a)

																	Quarter Ended March 31,
																	2020		2019
																	$		$		Variance		%
Revenue	$	68,650	$	32,381	$	36,269	112	%	$	156,139	$	85,757	$	70,382	82	%	$	180,799	$	128,573	$	52,226	41	%
Cost of revenue		16,742		7,112		9,630	135	%		38,907		21,946		16,961	77	%
Gross profit		51,908		25,269		26,639	105	%		117,232		63,811		53,421	84	%
Expenses:
Cost of revenue (exclusive of depreciation and amortization shown separately below)																		72,382		44,677		27,705	62	%
Operating expenses:
Advertising and marketing		14,328		9,046		5,282	58	%		39,222		24,900		14,322	58	%		32,515		26,404		6,111	23	%
Sales		11,393		7,662		3,731	49	%		26,705		18,792		7,913	42	%		17,940		16,212		1,728	11	%
Technology and development		9,964		5,867		4,097	70	%		24,013		15,921		8,092	51	%		19,257		15,987		3,270	20	%
Legal		105		1,033		(928)	-90	%		725		3,348		(2,623)	-78	%
Regulatory		777		817		(40)	-5	%		2,771		2,437		334	14	%
Legal and regulatory																		1,222		1,586		(364)	-23	%
Acquisition and integration related costs		8,526		6,196		2,330	38	%		10,639		6,959		3,680	53	%		3,664		1,012		2,652	262	%
General and administrative		21,938		12,298		9,640	78	%		52,299		35,215		17,084	49	%		45,120		35,982		9,138	25	%
Depreciation and amortization		6,418		2,607		3,811	146	%		11,693		5,673		6,020	106	%		9,710		9,600		110	1	%
Loss from operations		(21,541)		(20,257)		(1,284)	6	%		(50,835)		(49,434)		(1,401)	3	%		(21,011)		(22,887)		1,876	-8	%
Amortization of warrants and loss on extinguishment of debt		1,457		8,454		(6,997)	-83	%		1,457		8,454		(6,997)	-83	%
Interest expense, net		8,202		873		7,329	839	%		9,678		1,707		7,971	467	%		9,303		6,521		2,782	43	%
Net loss before taxes		(31,200)		(29,584)		(1,616)	5	%		(61,970)		(59,595)		(2,375)	4	%		(30,314)		(29,408)		(906)	3	%
Income tax provision		130		188		(58)	-31	%		429		360		69	19	%
Income tax (benefit) expense																		(711)		742		(1,453)	-196	%
Net loss	$	(31,330)	$	(29,772)	$	(1,558)	5	%	$	(62,399)	$	(59,955)	$	(2,444)	4	%	$	(29,603)	$	(30,150)	$	547	-2	%

~~Table of Contents~~

EBITDA and Adjusted EBITDA

The following table reconciles net loss to ~~EBTIDA~~EBITDA and Adjusted EBITDA for the quarters ended March 31, 2020 and ~~nine months ended September 30, 2017 and 2016:~~2019:


	Quarter Ended
	March 31,
	2020		2019
Net loss	$	(29,603)	$	(30,150)
Add:
Interest expense, net		9,303		6,521
Income tax (expense)/benefit		(711)		742
Depreciation expense		851		863
Amortization expense		8,859		8,737
EBITDA(1)		(11,301)		(13,287)
Stock-based compensation		18,315		13,523
Acquisition and integration related costs		3,664		1,012
Adjusted EBITDA(1)	$	10,678	$	1,248

Three Months Ended

Nine Months Ended

September 30,

September 30,


2017

2016

2017

2016

Net loss

$
(31,330)

$
(29,772)

$
(62,399)

$
(59,955)

Add:

Interest expense, net

8,202

873

9,678

1,707

Income tax provision

130

188

429

360

Depreciation expense

1,113

606

2,466

1,542

Amortization expense

5,305

2,001

9,227

4,131

EBITDA(1)

(16,580)

(26,104)

(40,599)

(52,215)

Stock-based compensation

5,966

2,165

13,628

5,087

Amortization of warrants and loss on extinguishment of debt

1,457

8,454

1,457

8,454

Acquisition and integration related costs

8,526

6,196

10,639

6,959

Adjusted EBITDA(1)

$
(631)

$
(9,289)

$
(14,875)

$
(31,715)

(1)

~~(1)~~

Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use EBITDA and Adjusted EBITDA, which are non-U.S. GAAP financial

Table of Contents

measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize Adjusted EBITDA as the primary measure of our performance.

EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, depreciation and amortization. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation ~~amortization of warrants and loss on extinguishment of debt~~ and acquisition and integration related costs. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

We believe both financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA and Adjusted EBITDA may vary from that of others in our industry. Neither EBITDA nor Adjusted EBITDA should be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

EBITDA and Adjusted EBITDA have important ~~limitation~~limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:

~~EBTIDA and Adjusted EBITDA:~~

●

~~does~~EBITDA and Adjusted EBITDA do not reflect the significant interest expense on our debt; ~~and~~

●

~~eliminates~~EBITDA and Adjusted EBITDA eliminate the impact of income taxes on our results of operations; ~~and~~

●

although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and both measures do not reflect any expenditures for such replacements; and

~~Table of Contents~~

~~does not reflect the significant non-recurring charge associated with the amortization of warrants and loss on extinguishment of debt; and~~

Adjusted EBITDA does not reflect the significant acquisition and integration related costs related to mergers and acquisitions; ~~and~~

●

Adjusted EBITDA does not reflect the significant ~~non cash~~non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and

●

other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than we do, limiting the usefulness of EBITDA and Adjusted EBITDA as comparative measures.

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and both EBITDA and Adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using EBITDA and Adjusted EBITDA along with other comparative tools, together with U.S. GAAP measurements, to assist in the evaluation of operating performance. Such U.S. GAAP measurements include ~~gross profit,~~ net loss, net loss per share and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

Consolidated Results of Operations Discussion

We completed our ~~acquisitions~~acquisition of ~~Best Doctors and HealthiestYou~~MedecinDirect on ~~July 14, 2017 and July 1, 2016, respectively.~~April 30, 2019. The results of operations of the aforementioned ~~acquisitions have~~acquisition has been included in our unaudited consolidated financial statements included in this Quarterly Report ~~since completion~~from the date of ~~the acquisitions.~~acquisition.

Revenue. Total revenue was ~~$68.7~~$180.8 million ~~including $21.8 million from Best Doctors~~ for the quarter ended ~~September 30, 2017,~~March 31, 2020, compared to ~~$32.4~~$128.6 million during the quarter ended ~~September 30, 2016,~~March 31, 2019, an increase of ~~$36.3~~$52.2 million, or ~~112%~~41%, with organic growth ~~was 45%. Total revenue was $156.1 million for the nine months ended September 30, 2017, compared to $85.8 million during the nine months ended September 30, 2016, an increase~~

Table of ~~$70.4 million, or 82%. Excluding the contribution of $21.8 million from Best Doctors our organic growth rate for the period was 57%.~~Contents

reflecting a 40% increase. The primary increase in revenue ~~for both periods~~ in ~~2017~~2020 was substantially driven by ~~the acquisition of Best Doctors contributing $21.8 million in revenue, and~~ an increase in new Clients and the number of new Members generating additional subscription access ~~fees.~~fees and an increase in volume associated with the COVID-19 pandemic. Subscription access fee revenue increased to $137.1 million or 29% for the quarter ended March 31, 2020. The increase in subscription access fees was due to the addition of new Clients and direct-to-consumer members, as the number of paid Members increased by ~~33%~~61% from ~~September 30, 2016~~March 31, 2019 to ~~September 30, 2017.~~March 31, 2020. Revenue from ~~the~~ U.S. subscription access fees was ~~$51.6~~$107.9 million ~~which includes $11.6~~for the quarter ended March 31, 2020 compared to $81.0 million ~~from Best Doctors. Best Doctors~~for the quarter ended March 31, 2019. We generated ~~$8.2~~$29.1 million of international subscription access fees for the quarter ended ~~September 30, 2017. Revenue from the U.S. subscription access fees were $123.4~~March 31, 2020 and $25.0 million ~~including $11.6 million from Best Doctors and $8.2 million of international subscription fees generated by Best Doctors~~ for the ~~nine months~~quarter ended ~~September 30, 2017.~~ March 31, 2019.

We completed approximately ~~306,000~~2.0 million visits, representing ~~$8.9~~$43.7 million of visit fees for the quarter ended ~~September 30, 2017,~~March 31, 2020, compared to approximately ~~203,000~~1.1 million visits, representing ~~$4.6~~$22.6 million of visit fees during the quarter ended ~~September 30, 2016, an~~March 31, 2019. The increase in visit fees is associated with the aforementioned increase in paid Members as well as the impact of ~~$4.3 million, or 94%. Revenue from general medical visits and other specialty visits (primarily expert second opinions)~~COVID-19.

Cost of Revenue. Cost of revenue was ~~$6.8 million and $2.1~~$72.4 million for the quarter ended ~~September 30, 2017, respectively. We also completed approximately 1,000,000 visits, representing $24.5 million of visit fees for the nine months ended September 30, 2017,~~March 31, 2020 compared to approximately 642,000 visits, representing $15.7 million of visit fees during the nine months ended September 30, 2016, an increase of $8.9 million, or 57%. Revenues from general medical visits and other specialty visits (primarily expert second opinions) was $22.4 million and $2.1 million for the nine months ended September 30, 2017, respectively.

~~Cost of Revenue.~~ ~~Cost of revenue was $16.7~~$44.7 million for the quarter ended ~~September 30, 2017 compared to $7.1 million for the quarter ended September 30, 2016,~~March 31, 2019, an increase of ~~$9.6~~$27.7 million, or ~~135%. Cost of revenue was $38.9 million for the nine months ended September 30, 2017 compared to $21.9 million for the nine months ended September 30, 2016, an increase of $17.0 million, or 77%~~62%. The increase ~~in both periods in 2017~~ was primarily due to ~~the the additional $7.0 million in costs associated with Best Doctors services, and~~ increased general medical visits and behavioral health visits resulting in increased provider fees, additional incentive fees paid to physicians and ~~increased~~ physician network operation center costs.

~~Gross Profit.~~ ~~Gross profit was $51.9 million, or 76% as a percentage~~ The cost of revenue for March 31, 2020 also reflects approximately $4.0 million for additional investments in capacity expansion associated with the ~~quarter ended September 30, 2017 compared to $25.3 million, or 78%, as a percentage~~global outbreak of revenue, for the quarter ended September 30, 2016, an increase of $26.6 million, or 105%. Gross profit was $117.2 million, or 75% as a percentage of revenue, for the nine months ended September 30, 2017 compared to $63.8 million, or 74%, as a percentage of revenue, for the nine

~~Table of Contents~~

~~months ended September 30, 2016, an increase of $53.4 million, or 84%. The increase in both periods reflects the aforementioned revenue and cost of revenue growth.~~COVID-19.

Advertising and Marketing Expenses. Advertising and marketing expenses were ~~$14.3~~$32.5 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to ~~$9.0~~$26.4 million for the quarter ended ~~September 30, 2016,~~March 31, 2019, an increase of ~~$5.3~~$6.1 million, or ~~58%~~23%. ~~Including the impact from Best Doctors, this~~This increase primarily consisted of increased digital advertising, member engagement and acquisition initiatives, sponsorship of professional organizations and trade shows of ~~$3.7 million, increased staffing of $1.1~~$5.1 million and ~~other~~increases in employee-related expenses and others of ~~$0.5~~$1.0 million. Advertising and marketing expenses were $39.2 million for the nine months ended September 30, 2017 compared to $24.9 million for the nine months ended September 30, 2016, an increase of $14.3 million, or 58%. Including the impact from Best Doctors, this increase primarily consisted of increased digital advertising, member engagement initiatives, sponsorship of professional organizations and trade shows of $11.2 million, increased staffing of $2.3 million and other expenses of $0.8 million.

Sales Expenses. Sales expenses were ~~$11.4~~$17.9 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to ~~$7.7~~$16.2 million for the quarter ended ~~September 30, 2016,~~March 31, 2019, an increase of ~~$3.7~~$1.7 million, or ~~49%~~11%. ~~Including the impact from Best Doctors, this~~This increase primarily consisted of increased staffing and sales commissions of ~~$3.3~~$2.3 million and ~~an increase~~offset by a decrease to other sales expenses of ~~$0.4~~$0.6 million. Sales expenses were $26.7 million for the nine months ended September 30, 2017 compared to $18.8 million for the nine months ended September 30, 2016, an increase of $7.9 million, or 42%. Including the impact from Best Doctors, this increase primarily consisted of increased staffing and sales commissions of $7.2 million and an increase to other sales expenses of $0.7 million.

Technology and Development Expenses. Technology and development expenses were ~~$9.9~~$19.3 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to ~~$5.8~~$16.0 million for the quarter ended ~~September 30, 2016,~~March 31, 2019, an increase of ~~$4.1~~$3.3 million, or ~~70%~~20%. ~~Including the impact from Best Doctors, this~~This increase resulted primarily from hiring additional personnel totaling ~~$2.3 million, technology and development expense of $1.4~~$1.9 million and other professional expenses of ~~$0.4~~$1.4 million. ~~Technology~~

Legal and ~~development~~Regulatory Expenses. Legal and regulatory expenses were $24.0 million for the nine months ended September 30, 2017 compared to $15.9 million for the nine months ended September 30, 2016, an increase of $8.1 million, or 51%. Including the impact from Best Doctors, this increase resulted primarily from hiring additional personnel totaling $5.4 million and technology and development expense of $2.6 million.

~~Legal Expenses.~~ ~~Legal expenses were $0.1~~$1.2 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to $1.6 million for the quarter ended March 31, 2019, a decrease of $0.4 million, or 23%. The decrease in 2020 resulted primarily from timing associated with activities to support litigation.

Acquisition and Integration Related Costs. Acquisition and integration related costs, incurred primarily in connection with integration activities of prior acquisitions as well as costs associated with the pending In Touch Technologies, Inc. acquisition, were $3.7 million for the quarter ended March 31, 2020 compared to $1.0 million for the quarter ended September 30, 2016, a decrease of $0.9 million, or 90%. Legal expenses were $0.7 million for the nine months ended September 30, 2017 compared to $3.3 million for the nine months ended September 30, 2016, a decrease of $2.6 million, or 78%. The decrease in both periods resulted primarily from lower legal fees incurred in connection with the Company’s legal activities in Texas.

~~Regulatory Expenses.~~ Regulatory expenses were $0.8 million for each of the quarters ended September 30, 2017 and 2016. Regulatory expenses were $2.8 million for the nine months ended September 30, 2017 compared to $2.4 million for the nine months ended September 30, 2016,March 31, 2019, an increase of ~~$0.4 million, or 14%. This increase resulted primarily from the increased activities required in connection with the Company’s legal efforts in Texas and certain other states.~~

~~Acquisition and Integration Related Costs.~~ Acquisition and integration related costs were $8.5 million for the quarter ended September 30, 2017 compared to $6.2 million for the quarter ended September 30, 2016, an increase of $2.3 million. Acquisition and integration related costs were $10.6 million for the nine months ended September 30, 2017 compared to $7.0 million for the nine months ended September 30, 2016, an increase of $3.6$2.7 million. The ~~2017~~2020 and 2019 acquisition and integration related costs represent investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration and ~~professional fees for the July 2017 acquisition of Best Doctors. The 2016 acquisition~~certain other non-recurring transaction costs related ~~costs represent legal, professional~~to mergers and ~~contract termination costs for the July 2016 HealthiestYou transaction.~~acquisitions.

General and Administrative Expenses. General and administrative expenses were ~~$21.9~~$45.1 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to ~~$12.3~~$36.0 million for the quarter ended ~~September 30, 2016,~~March 31, 2019, an increase of ~~$9.6~~$9.1 million, or ~~78%~~25%. This increase was driven primarily by an increase in employee-related expenses of approximately ~~$6.7~~$4.6 million resulting from growth in total employee headcount to ~~1,247~~2,588 at ~~September 30, 2017~~March 31, 2020 as compared to ~~658~~2,046 employees at ~~September 30, 2016 primarily from~~March 31, 2019 reflecting the impact ~~from~~of the ~~Best Doctors acquisition.~~MedecinDirect acquisitions and to support the increase volume of activities due to COVID-19. Other expenses, which include office-related charges, professional fees and bank charges, increased by ~~$2.9~~$4.6 million for the quarter ended ~~September, 2017~~March 31, 2020 as compared to September 30, 2016, to support the growth of our business including the impact from the Best Doctors acquisition. General and administrative expenses were $52.3 million for the nine months ended September 30, 2017 compared to $35.2 million for the nine months ended September 30, 2016, an increase of $17.1 million, or 49%. This

~~Table of Contents~~

increase was driven primarily by an increase in employee-related expenses of approximately $11.6 million resulting from growth in total employee headcount to 1,247 at September 30, 2017 as compared to 658 at September 30, 2016 including the impact from the Best Doctors acquisition. Other expenses, which include office-related charges and bank charges, increased by $5.5 million for the nine months ended September 30, 2017 as compared to September 30, 2016 to support the growth of our business including the impact from the Best Doctors acquisition. March 31, 2019.

Depreciation and Amortization. Depreciation and amortization ~~was $6.4~~were $9.7 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to ~~$2.6~~$9.6 million for the quarter ended ~~September 30, 2016,~~March 31, 2019, an increase of ~~$3.8~~$0.1 million, or 146%. Depreciation and amortization was $11.7 million for the nine months ended September 30, 2017 compared to $5.7 million for the nine months ended September 30, 2016, an increase of $6.0 million, or 106%1%. The increase ~~in both periods~~ was primarily due to ~~additional~~the impact from acquisitions in 2019. Additional amortization expenses primarily related

Table of Contents

to ~~the Best Doctors~~an increase in acquisition-related intangible assets that ~~grew~~increased from ~~$36.1~~$305.4 million at ~~September 30, 2016~~March 31, 2019 to ~~$185.5~~$317.1 million at ~~September 30, 2017~~March 31, 2020 and an increase of depreciation expense on an increased base of depreciable fixed assets ~~including the impact~~that increased from ~~the Best Doctors acquisition that grew from $10.7~~$23.0 million at ~~September 30, 2016~~March 31, 2019 to ~~$17.3~~$26.2 million at ~~September 30, 2017.~~March 31, 2020..

~~Amortization of Warrants and Loss on Extinguishment of Debt.~~ Amortization of warrants and loss on extinguishment of debt was $1.5 million for the quarter and nine months ended September 30, 2017 compared to $8.5 million for the quarter and nine months ended September 30, 2016, a decrease of $7.0 million. As a result of the July 2017 refinancing, the Company paid off the July 2016 Mezzanine Term Loan and recorded a one-time charge associated with the loss on extinguishment of debt of $1.5 million. As a result of the July 2016 refinancing, the Company determined that the July 2016 Mezzanine Term Loan represents an extinguishment of the original SVB Mezzanine Term Loan and recorded a one-time charge associated with the amortization of warrants and loss on extinguishment of debt of $8.5 million in 2016. The amortization of warrants and loss on extinguishment of debt includes the write-off of fees paid to SVB, deferred debt costs associated with the original Mezzanine Term Loan and the $7.7 million non-cash fair value of the warrants issued in connection with the July 2016 Mezzanine Term Loan.

Interest Expense, Net. Interest expense, net consists of interest costs and amortization of debt discount associated with our ~~bank and other debt and~~Convertible Senior Notes, interest income from short-term investments in marketable ~~securities.~~securities as well as foreign exchange gain or loss. Interest expense, net was ~~$8.2~~$9.3 million for the quarter ended ~~September 30, 2017~~March 31, 2020 compared to ~~$0.9~~$6.5 million for the quarter ended ~~September 30, 2016. Interest expense, net was $9.7 million for the nine months ended September 30, 2017 compared to $1.7 million for the nine months ended September 30, 2016.~~March 31, 2019. The increase in net interest expense in ~~both periods in 2017~~2020 reflects ~~higher outstanding debt and costs~~interest expense accretion associated with ~~the~~our Convertible Senior Notes, lower interest income from short-term investments as well as higher foreign exchange loss.

Income tax (benefit) expense. Income tax benefit was $0.7 million for the quarter ended March 31, 2020 compared to an income tax expense $0.7 million for the quarter ended March 31, 2019 and is primarily reflective of the ~~July 2017 re-financing.~~jurisdiction mix of income in the first quarter of 2020.

Liquidity and Capital Resources

The following table presents a summary of our cash flow activity for the periods set forth below:


	Nine Months Ended
	September 30,
	2017		2016

					Quarter Ended
					March 31,
					2020		2019
Consolidated Statements of Cash Flows Data
Net cash used in operating activities	$	(27,166)	$	(44,341)	$	(6,320)	$	(7,892)
Net cash (used in) provided by investing activities		(456,721)		12,434		(11,928)		7,336
Net cash provided by financing activities		516,894		20,873		15,053		10,702
Total	$	33,007	$	(11,034)	$	(3,195)	$	10,146

~~Since our inception,~~Historically, we have financed our operations primarily through public and private sales of equity securities, debt issuance and bank borrowings.

On ~~July 14, 2017,~~April 30, 2019, we completed the ~~Company acquired Best Doctors.~~acquisition of MedecinDirect. The purchase price was ~~$445.5~~$11.2 million ~~consisting of $379.3~~cash with additional potential earnout consideration. We also made a $5.0 million ~~of cash and 1.9 million shares of Teladoc’s common stock valued at approximately $66.2 million on July 14, 2017.~~

On July 14, 2017 and concurrent with the consummation of the Best Doctors acquisition, the Company entered into a New Revolving Credit Facility of $10.0 million and a New Term Loan Facility of $175.0 million which resultedminority investment in ~~net proceeds of $166.7 million after debt issuance related costs.~~

~~Table of Contents~~

On July 13, 2017, the Company repaid all the outstanding amounts under both the SVB Line of Credit Facility and the Mezzanine Term Loan of $17.5 million and $25 million, respectively, including early termination and final deferred origination fees of $1.7 million.

In June 2017, the Company issued, at par value, $275 million aggregate principal amount of 3% convertible senior notes due 2022. The 2022 Notes bear cash interest at a rate of 3% per year, payable semi-annually in arrearsVida Health on June 15 and December 15 of each year, beginning on December 15, 2017. The 2022 Notes will mature on December 15, 2022. The net proceeds to the Company from the offering were $263.7 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by the Company.

In January 2017, we received $123.9 million of net cash proceeds associated with the issuance of 7,887,500 shares of common stock in conjunction with our Follow-On Offering, after deducting underwriting discounts and commissions of $7.6 million as well as other offering expenses of $0.6 million.

In July 2015, we received $163.1 million of net cash proceeds associated with the issuance of 9,487,500 shares of common stock in conjunction with our IPO, after deducting underwriting discounts and commissions of $12.6 million as well as other offering expenses of $4.5 million.19, 2019.

Our principal sources of liquidity are cash and cash equivalents totaling ~~$83.1~~$508.0 million as of ~~September 30, 2017,~~March 31, 2020, which were held for working capital purposes. Our cash and cash equivalents are comprised of money market funds and marketable securities. Additionally, we have short term marketable securities of ~~$89.8~~$2.8 million as of ~~September 30, 2017.~~March 31, 2020.

Cash Used in Operating Activities

For the ~~nine~~three months ended ~~September 30, 2017,~~March 31, 2020, cash used in operating activities was ~~$27.2~~$6.3 million. The negative cash flows resulted primarily from our net loss of ~~$62.4~~$29.6 million, changes in deferred income tax of $2.8 million and adjusted for the effect of net changes in working capital and other balance sheet accounts largely associated with the Company’s annual bonus payment in March resulting in cash outflows of approximately $11.6 million. These are partially offset by depreciation and amortization of ~~$11.7~~$11.2 million, allowance for doubtful accounts of $1.3 million, stock-based compensation of ~~$13.6~~$18.3 million ~~deferred income tax of $0.2 million,~~and accretion of interest ~~$3.3 million, loss on extinguishment~~ of debt of $1.5 million as well as the effect of changes in working capital and other balance sheet accounts resulting in cash outflows of approximately $3.6 million, all of which was used to support the growth of the business. Included in cash used in operating activities is approximately $10.6 million of one-time costs associated with acquisition and integration related costs.$6.9 million.

For the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2019, cash used in operating activities was ~~$44.3~~$7.9 million. The negative cash flows resulted primarily from our net loss of ~~$60.0~~$30.2 million, ~~as well as the effect~~adjusted for deferred income tax of ~~changes in working capital and other balance sheet accounts resulting in cash outflows of approximately $5.3~~$2.7 million, ~~all of which was used to support the growth of the business. The impact was~~ partially offset by depreciation and amortization of ~~$5.7~~$11.6 million, allowance for doubtful accounts of ~~$2.0~~$0.8 million, stock-based compensation of ~~$5.2 million, deferred income tax of $0.4~~$13.5 million and ~~amortization~~accretion of ~~warrants~~interest of ~~$7.7~~$6.1 million. ~~Included in cash used in operating activities is approximately $7.0 million of acquisition and integration related costs.~~

The decrease in cash used in operating activities for the three months ended March 31, 2020 and March 31, 2019 was primarily the result of ~~increased gross profit resulting from~~ the ~~growth in revenue~~aforementioned annual bonus payment partially offset by ~~additional headcount, increased advertising and marketing expenses, costs incurred~~the Company’s ability to ~~improve and optimize~~continue to increase our ~~technology platform, increases in~~revenue dollars while gaining operating leverage on our ~~provider network operations center and office-related charges to support the growth~~cash related operating expenses.

Table of ~~our business.~~Contents

Cash (Used in) Provided by Investing Activities

Cash used in investing activities was ~~$456.7~~$11.9 million for the ~~nine~~three months ended ~~September 30, 2017.~~March 31, 2020. Cash used in investing activities consisted of the ~~acquisition~~purchases of ~~Best Doctors~~property and equipment totaling $0.9 million, investments in internally developed capitalized software of ~~$379.4~~$2.0 million, ~~net~~and $9.0 million of ~~cash acquired, purchases and~~pre-funding associated with the pending InTouch Technologies, Inc. acquisition.

Cash provided by investing activities was $7.3 million for the three months ended March 31, 2019. Cash provided by investing activities consisted of maturities of short-term marketable securities of ~~$73.8~~$9.0 million, net of sales, ~~and of~~offset by the purchases of property and equipment totaling ~~$2.0~~$0.6 million and investments in internally developed capitalized software of ~~$1.5~~$1.1 million.

Cash provided by investing activities was $12.4 million for the nine months ended September 30, 2016. Cash provided by investing activities consisted of purchases and maturities of short-term marketable securities of $51.4 million, net of sales, offset by the acquisition of HealthiestYou of $37.0 million net of cash acquired, and of purchases of property and equipment totaling $1.1 million and investments in internally developed capitalized software of $0.8 million.

~~Table of Contents~~

Cash Provided by Financing Activities

Cash provided by financing activities for the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2020 was ~~$517.1~~$15.1 million. Cash provided by financing activities consisted of $263.7 million of net cash proceeds from the issuance of convertible senior notes, $123.9 million of net cash proceeds from our Follow-Up Offering in January 2017, $166.7 million of proceeds under the credit facilities, $6.9$14.9 million of proceeds from the exercise of employee stock options ~~$1.3~~and $0.2 million of timing associated with cash proceeds ~~from employee stock purchase plan and $0.5 million of~~for tax withholding for options exercised, offset by the repayment of $44.1 million under the SVB Mezzanine Term Loan and the Revolving Advance Facility and repayment of $2.0 million under the Amended and Restated Subordinated Promissory Note.exercised.

Cash provided by financing activities for the ~~nine~~three months ended ~~September 30, 2016~~March 31, 2019 was ~~$20.9~~$10.7 million. Cash provided by financing activities consisted of $8.9 million of proceeds from the exercise of employee stock options ~~of $2.3 million, proceeds from the issuance of common stock of $0.2 million~~ and ~~$17.5 million borrowed under the Revolving Advance Facility and $0.6~~$1.8 million of timing associated with cash proceeds for tax withholding for options ~~exercised, offset by~~exercised.

Looking Forward

At March 31, 2020, the ~~repayment of $11.7 million under the Amended Term Loan Facility.~~

~~Looking Forward~~

As a result of our January 2017 Follow-On Offering, we received $123.9 million of net cash proceeds. Additionally in June 2017, we issued Convertible Senior Notes with net proceeds of $263.7 million and in July 2017, we entered into New Senior Secured Credit Facilities with net proceeds of $166.7 million. In July 2017, we acquired Best Doctors for approximately $379.4 million inCompany’s cash and short-term investments were $510.8 million. For the three months ended March 31, 2020, we ~~paid off~~have experienced positive Adjusted EBITDA and for the ~~entire SVB Facilities plus other deal related costs amounting to approximately $53.7 million. Currently,~~full year 2020 we anticipate ~~negative~~positive Adjusted EBITDA ~~results for 2017.~~as well as positive free cash flow.

We believe that our existing cash and cash equivalents and short-term marketable securities will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of visits, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced service offerings and the continuing market acceptance of telehealth. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies and intellectual property rights. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, financial condition and results of operations would be adversely affected.

~~2016~~ Shelf Registration ~~Statement~~Statements

We filed aan automatically effective shelf registration statement on Form S-3 under the Securities Act on ~~September 30, 2016, which was declared effective October 5, 2016, the “2016~~November 28, 2017 (the “2017 Shelf”). Under the ~~2016~~2017 Shelf at the time of effectiveness, we had the ability to raise up to ~~$300~~$175 million by selling common stock in addition to ~~2,000,000~~1,200,000 shares of common stock eligible for resale by certain shareholders. We currently have the ability under the 2017 Shelf to raise up to approximately $32 million by selling common stock in addition to 370,000 shares of common stock eligible for resale by certain existing shareholders.

~~In January 2017,~~On July 23, 2018, we ~~successfully closed~~filed an automatically effective universal shelf registration statement on ~~our Follow-On Offering in which~~Form S-3 under the ~~Company issued and sold 7,885,500 shares~~Securities Act (the “2019 Shelf”). The 2019 Shelf registers the offering of securities, including common stock, ~~including the exercise of an underwriter option to purchase additional shares~~preferred stock and 1,600,000 shares offered by certain stockholders of the Company, at an issuance price of $16.75 per share. We received net proceeds of $123.9 million after deducting underwriting discounts and commissions of $7.6 million as well as other offering expenses of $0.6 million.

~~Indebtedness~~

On July 14, 2017 and concurrent with the consummation of the Best Doctors acquisition, the Company entered into a $175.0 million Senior Secured Term Loan Facility (the “New Term Loan Facility”) and a $10.0 million Senior Secured Revolving Credit Facility (the “New Revolving Credit Facility” and together with the New Term Loan Facility, the “New Senior Secured Credit Facilities”) pursuant to a credit agreement by and among the Company, the lenders party theretodebt securities, that we may issue from time to time in amounts to be determined, as well as the issuance of common stock by selling stockholders. Issuances of securities under the 2019 Shelf require the filing of a prospectus supplement identifying the amount and ~~Jefferies Finance LLC, as administrative agent and collateral agent. The New Term Loan Facility has been used to fund the expansion~~terms of the ~~Company’s business~~securities to be issued. Our ability to issue securities is subject to market conditions and ~~the~~other factors impacting our borrowing capacity.

Indebtedness

We entered into a $10.0 million New Revolving Credit Facility in 2017. The New Revolving Credit Facility is available for working capital and other general corporate purposes. We have maintained the New Revolving Credit Facility and, there was no amount outstanding as of March 31, 2020 and December 31, 2019. The Company utilized $2.2 million of letters of credit for facility security deposits and credit card at March 31, 2020 and December 31, 2019,

Table of Contents

respectively.

On May 8, 2018, we issued, at par value, $287.5 million aggregate principal amount of 1.375% convertible senior notes due 2025. The ~~New Term Loan Facility carries~~2025 Notes bear cash interest at a rate of ~~7.25% above fixed 90 days Libor~~1.375% per year, payable semi-annually in arrears on May 15 and November 15 of ~~1.24% (or 8.49%)~~each year. The 2025 Notes will mature on May 15, 2025. The net proceeds to us from the offering were $279.1 million after deducting offering costs of approximately $8.4 million.

The 2025 Notes are senior unsecured obligations of ours and ~~matures~~rank senior in ~~July 2022. Interest payments are payable monthly~~right of payment to our indebtedness that is expressly subordinated in ~~arrears. The New Revolving Credit Facility carries~~

~~Table~~right of ~~Contents~~

~~interest at a rate~~payment to the 2025 Notes; equal in right of ~~7.25% above fixed 90- days Libor~~payment to our liabilities that is not so subordinated; effectively junior in right of ~~1.24% and matures in July 2020. The Company is also required~~payment to ~~pay a commitment fee on~~any of our secured indebtedness to the ~~average daily unused portion~~extent of the ~~New Revolving Credit Facility at 0.50%. The Company~~value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities incurred ~~expenses of $8.3 million in conjunction with obtaining the New Senior Secured Credit Facilities.~~by our subsidiaries.

In June 2017, ~~the Company~~we issued, at par value, $275 million aggregate principal amount of 3% convertible senior notes due ~~2022 (the “2022 Notes”).~~2022. The 2022 Notes bear cash interest at a rate of 3% per year, payable semi-annually in arrears on June 15 and December 15 of each ~~year, beginning on December 15, 2017.~~year. The 2022 Notes will mature on December 15, 2022. The net proceeds to ~~the Company~~us from the offering were $263.7 million after deducting offering costs of approximately $11.3 million.

The 2022 Notes are senior unsecured obligations of ~~the Company~~ours and rank senior in right of payment to ~~the Company’s~~our indebtedness that is expressly subordinated in right of payment to the 2022 Notes; equal in right of payment to ~~the Company’s~~our liabilities that is not so subordinated; effectively junior in right of payment to any of ~~the Company’s~~our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities incurred by our subsidiaries. See Note 11, “Convertible Senior Notes” of the ~~Company’s subsidiaries.~~

~~Holders may convert all or any portion of their 2022~~ Notes ~~in integral multiples of $1,000 principal amount, at their option, at any time prior~~ to the ~~close~~Consolidated Financial Statements of ~~business~~the Quarterly Report on Form 10-Q for additional information on the ~~business day immediately preceding June 15, 2022 only under the following circumstances:~~

~~•during the five business day period after any ten consecutive trading day period (the ‘‘measurement period’’) in which the trading price (as defined in the 2022~~2025 Notes ~~Indenture) per $1,000 principal amount of 2022 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock~~ and ~~the conversion rate on each such trading day;~~

~~•upon the occurrence of specified corporate events described under the 2022 Notes Indenture; or~~

•on or after June 15, 2022, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2022 Notes, in integral multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.

The conversion rate for the 2022 Notes was initially, and remains, 22.7247 shares of the Company’s common stock per $1,000 principal amount of the 2022 Notes, which is equivalent to an initial conversion price of approximately $44.00 per share of the Company’s common stock. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. If the Company elects (or are deemed to have elected) to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of the Company’s common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 25 trading day observation period (as defined in the 2022 Notes Indenture).

The Company may redeem for cash all or any portion of the 2022 Notes, at its option, on or after December 22, 2020 if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including the trading day immediately preceding the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the 2022 Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any 2022 Note for redemption on or after December 22, 2020 will constitute a make-whole fundamental change with respect to that 2022 Note, in which case the conversion rate applicable to the conversion of that Note, if it is converted in connection with the redemption, will be increased in certain circumstances as described in the 2022 Notes Indenture.

~~Table of Contents~~

In accounting for the issuance of the 2022 Notes, the Company separated the 2022 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2022 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the five-year term of the 2022 Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component related to the 2022 Notes is $62.4 million, net of debt issuance costs and is recorded in additional paid-in capital on the accompanying condensed consolidated balance sheet. The Company has reserved 8.1 million shares of common stock for the 2022 Notes.

The fair value of the 2022 Notes was approximately $290 million as of September 30, 2017. The Company estimates the fair value of its 2022 Notes utilizing market quotations for debt that have quoted prices in active markets. Since the 2022 Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities, which are classified as Level 2 measurements within the fair value hierarchy. See Note 7, “Fair Value Measurements,” for definitions of hierarchy levels. As of September 30, 2017, the remaining contractual life of the 2022 Notes is approximately 5.5 years.

~~As discussed in Note 8 to the consolidated financial statements, the SVB Mezzanine Term Loan, the SVB Line of Credit Facility and Ameridoc Subordinated Promissory Note~~We were ~~paid off in the third quarter of 2017.~~

~~The Company was~~ in compliance with all debt covenants at ~~September 30, 2017~~March 31, 2020 and December 31, ~~2016.~~2019.

Contractual Obligations and Commitments

The following summarizes our contractual obligations as of ~~September 30, 2017:~~March 31, 2020:

Payment Due by Period




Less than

1 to 3

4 to 5

More than

Total

1 Year

Years

Years

5 Years

Operating leases

$
29,730

$
6,795

$
9,975

$
7,095

$
5,865

Obligations under the Senior Secured Credit Facilities

175,000

—

—

175,000

—

Obligations under the Convertible Notes

275,000

—

—

275,000

—

Interest associated with long term debt

110,215

23,108

46,215

40,892

—

Total

$
589,945

$
29,903

$
56,190

$
497,987

$
5,865


	Payment Due by Period
			Less than		1 to 3		4 to 5		More than
	Total		1 Year		Years		Years		5 Years
Operating leases	$	42,428	$	6,107	$	14,694	$	13,120	$	8,507
Debt obligations under the Convertible Notes		562,470		0	$	274,970	$	0	$	287,500
Interest associated with the Convertible Notes		38,728		12,202	$	18,126	$	7,906	$	494
Total	$	643,626	$	18,309	$	307,790	$	21,026	$	296,501

Our existing office and hosting co-location facilities lease agreements provide us with the option to renew and generally provide for rental payments on a graduated basis. Our future operating lease obligations would change if we entered into additional operating lease agreements as we expand our operations and if we exercised the office and hosting co-location facilities lease options. The contractual commitment amounts in the table above are associated with agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions and the approximate timing of the transaction. Obligations under contracts that we can cancel without a significant penalty are not included in the table above.

Off-Balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We are therefore not exposed to the financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market ~~Risk~~Risk

Interest Rate Risk and Foreign Exchange Risk

We do not have any floating rate debt with our ~~Term Loan~~New Revolving Credit Facility ~~and Revolving Advance Facility, and cash~~as of March 31, 2020. Cash equivalents that are subject to interest rate volatility ~~which is~~represent our principal market risk. ~~A 25 basis point change in the weighted average interest rate relating to the Term Loan facility and Revolving Advance facility as of September 30, 2017, which~~

~~Table of Contents~~

~~are subject to variable interest rates based on the LIBOR rate, would yield a change of approximately $438,000 in annual interest expense.~~ We do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates.

We operate our business primarily within the United States and currently execute ~~approximately 85%~~more than 84% of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our consolidated financial statements.

Concentrations of Risk and Significant Clients

No Client represented over 10% of revenues for the quarters ended March 31, 2020 and 2019.

No Client represented over 10% of accounts receivable at March 31, 2020 and December 31, 2019.

Item 4. Controls and ~~Procedures~~Procedures

Management’s Report on Internal Control over Financial Reporting

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of ~~September 30, 2017.~~

March 31, 2020.

No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended ~~September 30, 2017~~March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3530

Table of Contents

PART II - OTHER ~~INFORMATION~~INFORMATION

Item 1. Legal ~~Proceedings~~Proceedings

~~We are~~The Company is subject to legal proceedings, claims and litigation arising in the ordinary course of ~~our~~its business.

~~On April 29, 2015,~~ At March 31, 2020, the Company ~~filed a lawsuit against the Texas Medical Board,~~is not aware of any pending or ~~the TMB, in the United States District Court for the Western District of Texas, Austin Division, which we refer to as the District Court, alleging~~threatened litigation that the TMB’s adoption on April 10, 2015 of an amendment to 22 T.A.C. 190.8(1)(L) that would require a prior in-person examination for a doctor validly to prescribe any controlled substance to a patient in Texas constitutes a violation, ~~inter alia~~, of the Sherman Antitrust Act. The District Court held a hearing on May 22, 2015 on Teladoc’s motion for preliminary injunction of the effectiveness of such amendments, which otherwise was scheduled to take effect on June 3, 2015. On May 29, 2015, the District Court issued the preliminary injunction requested by Teladoc and enjoined the effectiveness of such rule amendment pending trial. On July 30, 2015, the TMB filed a motion to dismiss the suit, and the District Court denied this motion on December 14, 2015. On January 8, 2016, the TMB provided notice of its intent to appeal the District Court’s denial of its motion to dismiss to the U.S. Court of Appeals for the Fifth Circuit, which was filed on June 17, 2016 and voluntarily withdrawn by the TMB on October 17, 2016. On November 2, 2016, the District Court granted the parties’ joint motion to stay the trial case through April 19, 2017. On April 10, 2017, the District Court granted the parties’ joint motion to stay the trial case through September 1, 2017. On September 7, 2017, the District Court granted the parties’ joint motion to stay the trial case through November 30, 2017. Accordingly, no trial date has been set.

Business in the State of Texas accounted for approximately $12.4 million, or 8% and $15.1 million, or 12%, of the Company’s consolidated revenue for the nine months ended September 30, 2017 and during the year ended December 31, 2016, respectively. If the TMB’s revisions go into effect as written and Teladoc is unable to adapt its business model in compliance with the TMB rule, its ability to operate its business in the State of Texas could be materially adversely affected, which would have a material adverse effect on its business, ~~financial condition and~~ results of operations,. cash flows or financial condition should such litigation be resolved unfavorably.

On December 12, 2018, a purported securities class action complaint (Reiner v. Teladoc Health, Inc., et.al.) was filed in the United States District Court for the Southern District of New York (the “SDNY”) against the Company and certain of the Company’s officers and a former officer. The complaint is brought on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period March 3, 2016 through December 5, 2018. The complaint asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegedly false or misleading statements and omissions with respect to, among other things, the alleged misconduct of one of the Company’s previous Executive Officers. The complaint seeks certification as a class action and unspecified compensatory damages plus interest and attorneys’ fees. The Company believes that the claims against the Company and its officers are without merit, and the Company and its named officers intend to defend the Company vigorously, including filing a motion to dismiss the complaint.

On May 14, 2018, a purported class action complaint (Thomas v. Best Doctors, Inc.) was filed in the United States District Court for the District of Massachusetts against the Company’s wholly owned subsidiary, Best Doctors, Inc. The complaint alleges that on or about May 16, 2017, Best Doctors violated the U.S. Telephone Consumer Protection Act (TCPA) by sending unsolicited facsimiles to plaintiff and certain other recipients without the recipients’ prior express invitation or permission. The lawsuit seeks statutory damages for each violation, subject to trebling under the TCPA, and injunctive relief. The Company will vigorously defend the lawsuit and any potential loss is currently deemed to be immaterial.

Item 1A. Risk ~~Factors~~Factors

Other than the risk factor set forth below, there have been no material changes ~~from~~to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2016 (in response~~2019. For a discussion of potential risks and uncertainties related to our Company see the information in Part I, Item 1A ("Risk Factors") of our Annual Report on Form ~~10-K).~~ 10-K for the year ended December 31, 2019.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Special Note Regarding Forward-Looking Statements” section in Part I, Item 2, of this Quarterly Report on Form 10-Q. ~~Other events that we do not currently anticipate or that we currently deem immaterial may~~

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious outbreak, which has continued to spread, and the related adverse public health developments, including orders to shelter-in-place, travel restrictions and mandated business closures, have adversely affected workforces, organizations, customers, economies and financial markets globally, leading to an economic downturn and increased market volatility. It has also ~~affect our business, prospects, financial condition and results~~disrupted the normal operations of ~~operations.~~many businesses, including ours.

As we expand our international operations, we will increasingly face political, legal and compliance, operational, regulatory, economic and other risks that we do not face or that are more significant than in our domestic operations. Our exposure to these risks is expected to increase. These risks vary widely by country and include varying regional and geopolitical business conditions and demands, government intervention and censorship, discriminatory regulation, nationalization or expropriation of assets and pricing constraints. Our international products need to meet country-specific client and member preferencesThis outbreak, as well as ~~country-specific legal requirements,~~intensified measures undertaken to contain the spread of COVID-19, could cause disruptions and severely impact our business, including, ~~those~~but not limited to:

●

causing one or more of our Clients to file for bankruptcy protection or shut down;

●

reducing Client and Member subscription fees generated, as well as visit fees by other individuals, as a result of funding constraints related to loss of revenue or employment;

Table of Contents

●

negatively impacting collections of accounts receivable;

●

negatively impacting our ability to facilitate the provision of our services to Clients and other consumers; and

●

harming our business, results of operations and financial condition.

We cannot predict with any certainty whether and to ~~licensing, privacy, data storage, location, protection~~what degree the disruption caused by the COVID-19 pandemic and ~~security.~~

reactions thereto will continue, and expect to face difficulty accurately predicting our internal financial forecasts.

Our ~~international operations increase~~continued access to sources of liquidity also depend on multiple factors, including global economic conditions, the condition of global financial markets, the availability of sufficient amounts of financing and our ~~exposure~~operating performance. As of March 31, 2020, we had unused commitments under our revolving credit facility available to us of $10.0 million (without giving effect to approximately $2.2 million of letters of credit). There is no guarantee that additional debt financing will be available in the future to fund our obligations, or that it will be available on commercially reasonable terms, in which case we may need to seek other sources of funding. In addition, the terms of the agreements governing our current indebtedness include, and ~~require~~any future debt agreements could include, restrictive covenants, which could restrict our business operations.

The outbreak also presents challenges as our entire workforce is currently working remotely and shifting to assisting new and existing Clients, Members and other consumers, who are also generally working remotely.

It is not possible for us to ~~devote significant management resources~~accurately predict the duration or magnitude of the adverse results of the outbreak and its effects on our business, results of operations or financial condition at this time, but such effects may be material. The COVID-19 pandemic may also have the effect of heightening many of the other risks identified in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, such as those relating to ~~implement controls~~our indebtedness, our need to generate sufficient cash flows to service our indebtedness and ~~systems~~our ability to comply with the ~~privacy and data protection laws of non-U.S. jurisdictions and~~covenants contained in the anti-bribery, anti-corruption and anti-money laundering laws of the United States (including the FCPA) and the United Kingdom (including the Bribery Act 2010) and similar laws in other jurisdictions. Implementingagreements that govern our compliance policies, internal controls and other systems upon our expansion into new countries and geographies may require the investment of considerable management time and management, financial and other resources over a number of years before any significant revenues or profits are generated. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees, restrictions or outright prohibitions on the conduct of our business, and significant brand and reputational harm. We must regularly reassess the size, capability and location of our global infrastructure and make appropriate changes, and must have effective change management processes and internal controls in place to address changes in our business and operations. Our success depends, in part, on our ability to anticipate these risks and manage these difficulties, and the failure to do so could have a material adverse effect on our business, operating results, financial position, brand, reputation and/or long-term growth.indebtedness.

3632

Table of Contents

Our international operations require us to overcome logistical and other challenges based on differing languages, cultures, legal and regulatory schemes and time zones. Our international operations encounter labor laws, customs and employee relationships that can be difficult, less flexible than in our domestic operations and expensive to modify or terminate. In some countries we are required to, or choose to, operate with local business partners, which requires us to manage our partner relationships and may reduce our operational flexibility and ability to quickly respond to business challenges.

In some countries, we may be exposed to currency exchange controls or other restrictions that prevent us from transferring funds internationally or converting local currencies into U.S. dollars or other currencies. Fluctuations in foreign currency exchange rates may have an impact on our revenues, operating results and cash flows from our international operations. Some of our operations are, and are increasingly likely to be, in emerging markets where these risks are heightened. Any measures we may implement to reduce the effect of volatile currencies and other risks on our international operations may not be effective.

~~Our exposure to all of the above risks is expected to increase as we seek to grow our foreign operations over the next several years.~~

Item 6. Exhibits ~~and Reports on Form 8-K~~

Exhibit

~~A list of exhibits is set forth on the Exhibit~~ Index ~~immediately following the signature page of this Form 10-Q, and is incorporated herein by reference.~~

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed
Herewith

2.1

Agreement and Plan of Merger, dated January 11, 2020, by and among Teladoc Health, Inc., Jonata Sub One, Inc., Jonata Sub Two, Inc., InTouch Technologies, Inc. and Fortis Advisors LLC, as equity holder representative

8-K

001-37477

2.1

1/13/20

3.1

Sixth Amended and Restated Certificate of Incorporation of Teladoc, Inc.

8-K

001-37477

3.1

5/31/17

3.2

Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation of Teladoc, Inc.

8-K

001-37477

3.1

6/1/18

3.3

Second Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation of Teladoc, Inc.

8-K

001-37477

3.1

8/10/18

3.4

Fourth Amended and Restated Bylaws of Teladoc Health, Inc.

8-K

001-37477

3.1

2/25/19

10.1

Separation and Release of Claims Agreement, dated January 3, 2020, by and between Teladoc Health, Inc. and Peter McClennen.

10.2

Form of Performance Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2015 Incentive Award Plan

21.1

Subsidiaries of the Registrant.

31.1

Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Chief Executive Officer—Certification pursuant to Rule13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.

3733

Table of Contents

~~Exhibit~~

~~Index~~

Incorporated by Reference
Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed
Herewith

2.1

Amended and Plan of Merger, dated as of June 29, 2016, by and among Teladoc, Inc., Copper Acquisition Sub One, Inc., Copper Acquisition Sub Two, Inc., HY Holdings, Inc. and Frontier Fund IV, L.P., as stockholder representative.

8-K

001-37477

2.1

7/06/16

2.2

Agreement and Plan of Merger, dated as of June 19, 2017, by and among Teladoc, Inc., Barolo Acquisition Corp., Best Doctors Holdings, Inc., Shareholder Representative Services LLC, as stockholder representative, BBH Capital Partners IV, L.P. and BBH Capital Partners QP IV, L.P.

8-K

001-37477

2.1

6/20/17

2.3

Amendment to Agreement and Plan of Merger, dated as of July 14, 2017, by and among Teladoc, Inc., Best Doctors Holdings, Inc. and Shareholder Representative Services LLC, as stockholder representative

8-K

001-37477

2.1

7/18/17

3.1

Sixth Amended and Restated Certificate of Incorporation of Teladoc, Inc.

8-K

001-37477

3.1

5/31/17

3.2

Second Amended and Restated Bylaws of Teladoc, Inc.

8-K

001-37477

3.2

5/31/17

4.1

Specimen stock certificate evidencing shares of the common stock.

S-1/A

333-204577

4.5

6/24/15

4.2

Indenture, dated as of June 27, 2017, by and between Teladoc, Inc. and Wilmington Trust, National Association.

8-K

001-37477

4.1

6/29/17

4.3

Global 3.00% Convertible Senior Note due 2022, dated as of June 27, 2017.

8-K

001-37477

4.2

6/29/17

10.1

Form of Indemnification Agreement.

S-1/A

333-204577

10.7

6/18/15

10.2

Teladoc, Inc. 2015 Incentive Award Plan (as amended and restated effective May 25, 2017).

8-K

001-37477

10.1

5/31/17

10.3

Form of Stock Option Agreement under the Teladoc, Inc. 2015 Incentive Award Plan.

S-1/A

333-204577

10.11

6/18/15

10.4

Form of Restricted Stock Agreement under the Teladoc, Inc. 2015 Incentive Award Plan.

S-1/A

333-204577

10.12

6/18/15

10.5

Form of Restricted Stock Unit Agreement under the Teladoc, Inc. 2015 Incentive Award Plan.

S-1/A

333-204577

10.13

6/18/15

10.6

Teladoc, Inc. 2015 Employee Stock Purchase Plan.

S-1/A

333-204577

10.14

6/18/15

~~Table of Contents~~

10.7

Teladoc, Inc. Non-Employee Director Compensation Program.

10-Q

001-37477

10.7

8/12/15

10.8

Amended and Restated Executive Employment Agreement, dated June 16, 2015, by and between Teladoc, Inc. and Jason Gorevic.

S-1/A

333-204577

10.19

6/18/15

10.9

Amended and Restated Executive Employment Agreement, dated June 16, 2015, by and between Teladoc, Inc. and Mark Hirschhorn.

S-1/A

333-204577

10.20

6/18/15

10.10

Amended and Restated Executive Employment Agreement, dated June 16, 2015, by and between Teladoc, Inc. and Michael King.

S-1/A

333-204577

10.21

6/18/15

10.11

Amendment to Amended and Restated Executive Employment Agreement, by and between Teladoc, Inc. and Mark Hirschhorn

8-K

001-37477

10.1

12/30/16

10.12

Teladoc, Inc. 2017 Inducement Award Plan

S-8

333-219275

99.3

7/14/17

10.13

Form of Stock Option Agreement under the Teladoc, Inc. 2017 Inducement Award Plan

10-K

001-37477

10.17

3/01/17

10.14

Form of Restricted Stock Agreement under the Teladoc, Inc. 2017 Inducement Award Plan

10-K

001-37477

10.18

3/01/17

10.15

Form of Restricted Stock Unit Agreement under the Teladoc, Inc. 2017 Inducement Award Plan

10-K

001-37477

10.19

3/01/17

10.16

Debt Commitment Letter, dated June 20, 2017, by and among Teladoc, Inc., Jefferies Group LLC and Jefferies Finance LLC.

8-K

001-37477

10.1

6/21/17

10.17

Credit Agreement, dated as of July 14, 2017, by and among Teladoc, Inc., as Borrower, the Lenders from time to time party thereto, Jefferies Finance LLC, as Administrative Agent and Collateral Agent, and Jefferies Finance LLC, as Sole Lead Arranger and Bookrunner.

8-K

001-37477

10.1

7/18/17

21.1

Subsidiaries of the Registrant.

S-1

333-204577

21.1

5/29/15

31.1

Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*

31.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*

~~Table of Contents~~

~~32.1~~

~~Chief Executive Officer—Certification pursuant to Rule13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.~~ Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~32.2~~

Chief Financial Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance ~~Document.~~Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the

Inline XBRL document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Calculation Linkbase Document.

101.DEF

XBRL Definition Linkbase Document.

101.LAB

XBRL Taxonomy Label Linkbase Document.

101.PRE

XBRL Taxonomy Presentation Linkbase Document.

104

Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

* Filed herewith.

** Furnished herewith.

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TELADOC HEALTH, INC.

Date: ~~November 1, 2017~~April 29, 2020	By:	/s/ JASON GOREVIC
	Name:	Jason Gorevic
	Title:	Chief Executive Officer

Date: ~~November 1, 2017~~April 29, 2020	By:	/s/ ~~MARK HIRSCHHORN~~MALA MURTHY
	Name:	~~Mark Hirschhorn~~Mala Murthy
	Title:	~~Executive Vice President, Chief Operating Officer and~~ Chief Financial Officer

4135


	September 30,		December 31,
	2017		2016

Assets
Current assets:
Cash and cash equivalents	$	83,119	$	50,015
Short-term marketable securities		89,758		15,793
Accounts receivable, net of allowance of $2,989 and $2,422, respectively		26,995		13,806
Prepaid expenses and other current assets		7,484		3,103
Total current assets		207,356		82,717
Property and equipment, net		9,627		7,479
Goodwill		498,549		188,184
Intangible assets, net		164,570		24,875
Other assets		822		415
Total assets	$	880,924	$	303,670
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,852	$	2,236
Accrued expenses and other current liabilities		24,137		7,981
Accrued compensation		14,854		8,856
Other debt - current portion		—		2,000
Total current liabilities		40,843		21,073
Other liabilities		7,555		7,609
Deferred taxes		14,416		1,694
Long term bank and other debt, net		166,938		42,424
Convertible senior notes, net		204,393		—
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares and 75,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; 56,908,305 shares and 46,201,563 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively		57		46
Additional paid-in capital		710,010		435,551
Accumulated deficit		(267,194)		(204,726)
Accumulated other comprehensive income (loss)		3,906		(1)
Total stockholders’ equity		446,779		230,870
Total liabilities and stockholders’ equity	$	880,924	$	303,670


								Accumulated
				Additional				Other		Total
	Common Stock			Paid-In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Income		Equity
Balance as of December 31, 2016	46,201,563	$	46	$	435,551	$	(204,726)	$	(1)	$	230,870
Exercise of stock options	734,293		1		6,995		—		—		6,996
Exercise of warrants	138,903		—		—		—		—		—
Issuance of common stock under employee stock purchase plan	90,968		—		1,265		—		—		1,265
Issuance of common stock for the acquisition of Best Doctors	1,855,078		2		66,178		—		—		66,180
Equity component of Convertible Senior Notes, net of issuance costs	—		—		62,404		—		—		62,404
Stock-based compensation (1)	—		—		13,697		(69)		—		13,628
Follow-On Offering	7,887,500		8		123,920		—		—		123,928
Other comprehensive income, net of tax	—		—		—		—		3,907		3,907
Net loss	—		—		—		(62,399)		—		(62,399)
Balance as of September 30, 2017	56,908,305	$	57	$	710,010	$	(267,194)	$	3,906	$	446,779


	BestDoctors		HealthiestYou
Purchase price	$	459,225	$	151,484
Less:
Cash		13,690		6,204
Accounts receivable		11,205		1,184
Other assets		13,613		1,537
Client relationships		112,810		10,930
Non-compete agreements		-		70
Internal-use software		-		2,220
Trademarks		24,920		1,180
Accounts payable		(393)		(836)
Deferred taxes		(11,800)		—
Other liabilities		(12,337)		(2,847)
Goodwill	$	307,517	$	131,842


	Unaudited Pro Forma				Unaudited Pro Forma
	Quarters Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2017		2016		2017		2016
Revenue	$	72,562	$	56,106	$	217,506	$	163,718
Net loss	$	(31,281)	$	(33,278)	$	(65,532)	$	(74,889)


	September 30, 2017
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	68,137	$	14,982	$	—	$	83,119
Short-term marketable securities	$	—	$	89,758	$	—	$	89,758
Contingent liability (included in other liabilities)	$	—	$	—	$	3,991	$	3,991



Balance at December 31, 2016	$	3,678
Change in fair value		313
Fair value at September 30, 2017	$	3,991


	As of September 30,
Liability component	2017
Principal	$	275,000
Less: Debt issuance costs, net (1)		(70,607)
Net carrying amount	$	204,393


					Weighted-
			Weighted-		Average
	Shares	Number of	Average		Remaining	Aggregate
	Available	Shares	Exercise		Contractual	Intrinsic
	for Grant	Outstanding	Price		Life in Years	Value
Balance at December 31, 2016	343,216	6,839,868	$	11.70	8.64	$	36,795
Increase in Plan authorized shares	4,176,722	—	$	—	—	$	—
Restricted stock units granted	(342,524)	—	$	—	—	$	—
Stock option grants	(3,671,073)	3,671,073	$	25.02	—	$	—
Stock options exercised	—	(734,293)	$	9.53	—	$	14,301
Stock options forfeited	687,375	(681,759)	$	16.84	—	$	5,647
Balance at September 30, 2017	1,193,716	9,094,889	$	16.87	8.50	$	149,973
Vested or expected to vest at September 30, 2017		9,094,889	$	16.87	8.50	$	149,973
Exercisable at September 30, 2017		2,348,722	$	8.86	7.16	$	57,048


		Weighted-Average
		Grant Date
	Shares	Fair Value Per Share
Balance at December 31, 2016	—	$	—
Granted	342,524	$	33.19
Cancelled/Forfeited	(5,616)	$	30.50
Balance at September 30, 2017	336,908	$	33.23
Vested and deferred at September 30, 2017	—	$	—
Non-vested at September 30, 2017	336,908	$	33.23


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Net loss	$	(31,330)	$	(29,772)	$	(62,399)	$	(59,955)
Add:
Interest expense, net		8,202		873		9,678		1,707
Income tax provision		130		188		429		360
Depreciation expense		1,113		606		2,466		1,542
Amortization expense		5,305		2,001		9,227		4,131
EBITDA(1)		(16,580)		(26,104)		(40,599)		(52,215)
Stock-based compensation		5,966		2,165		13,628		5,087
Amortization of warrants and loss on extinguishment of debt		1,457		8,454		1,457		8,454
Acquisition and integration related costs		8,526		6,196		10,639		6,959
Adjusted EBITDA(1)	$	(631)	$	(9,289)	$	(14,875)	$	(31,715)


	Payment Due by Period
			Less than		1 to 3		4 to 5		More than
	Total		1 Year		Years		Years		5 Years
Operating leases	$	29,730	$	6,795	$	9,975	$	7,095	$	5,865
Obligations under the Senior Secured Credit Facilities		175,000		—		—		175,000		—
Obligations under the Convertible Notes		275,000		—		—		275,000		—
Interest associated with long term debt		110,215		23,108		46,215		40,892		—
Total	$	589,945	$	29,903	$	56,190	$	497,987	$	5,865


		Incorporated by Reference
Exhibit Number	Exhibit Description	Form	File No.	Exhibit	Filing Date	Filed Herewith

2.1	Amended and Plan of Merger, dated as of June 29, 2016, by and among Teladoc, Inc., Copper Acquisition Sub One, Inc., Copper Acquisition Sub Two, Inc., HY Holdings, Inc. and Frontier Fund IV, L.P., as stockholder representative.	8-K	001-37477	2.1	7/06/16

2.2	Agreement and Plan of Merger, dated as of June 19, 2017, by and among Teladoc, Inc., Barolo Acquisition Corp., Best Doctors Holdings, Inc., Shareholder Representative Services LLC, as stockholder representative, BBH Capital Partners IV, L.P. and BBH Capital Partners QP IV, L.P.	8-K	001-37477	2.1	6/20/17
2.3	Amendment to Agreement and Plan of Merger, dated as of July 14, 2017, by and among Teladoc, Inc., Best Doctors Holdings, Inc. and Shareholder Representative Services LLC, as stockholder representative	8-K	001-37477	2.1	7/18/17
3.1	Sixth Amended and Restated Certificate of Incorporation of Teladoc, Inc.	8-K	001-37477	3.1	5/31/17

3.2	Second Amended and Restated Bylaws of Teladoc, Inc.	8-K	001-37477	3.2	5/31/17

4.1	Specimen stock certificate evidencing shares of the common stock.	S-1/A	333-204577	4.5	6/24/15

4.2	Indenture, dated as of June 27, 2017, by and between Teladoc, Inc. and Wilmington Trust, National Association.	8-K	001-37477	4.1	6/29/17
4.3	Global 3.00% Convertible Senior Note due 2022, dated as of June 27, 2017.	8-K	001-37477	4.2	6/29/17
10.1	Form of Indemnification Agreement.	S-1/A	333-204577	10.7	6/18/15

10.2	Teladoc, Inc. 2015 Incentive Award Plan (as amended and restated effective May 25, 2017).	8-K	001-37477	10.1	5/31/17

10.3	Form of Stock Option Agreement under the Teladoc, Inc. 2015 Incentive Award Plan.	S-1/A	333-204577	10.11	6/18/15

10.4	Form of Restricted Stock Agreement under the Teladoc, Inc. 2015 Incentive Award Plan.	S-1/A	333-204577	10.12	6/18/15

10.5	Form of Restricted Stock Unit Agreement under the Teladoc, Inc. 2015 Incentive Award Plan.	S-1/A	333-204577	10.13	6/18/15

10.6	Teladoc, Inc. 2015 Employee Stock Purchase Plan.	S-1/A	333-204577	10.14	6/18/15

10.7	Teladoc, Inc. Non-Employee Director Compensation Program.	10-Q	001-37477	10.7	8/12/15

10.8	Amended and Restated Executive Employment Agreement, dated June 16, 2015, by and between Teladoc, Inc. and Jason Gorevic.	S-1/A	333-204577	10.19	6/18/15

10.9	Amended and Restated Executive Employment Agreement, dated June 16, 2015, by and between Teladoc, Inc. and Mark Hirschhorn.	S-1/A	333-204577	10.20	6/18/15

10.10	Amended and Restated Executive Employment Agreement, dated June 16, 2015, by and between Teladoc, Inc. and Michael King.	S-1/A	333-204577	10.21	6/18/15

10.11	Amendment to Amended and Restated Executive Employment Agreement, by and between Teladoc, Inc. and Mark Hirschhorn	8-K	001-37477	10.1	12/30/16

10.12	Teladoc, Inc. 2017 Inducement Award Plan	S-8	333-219275	99.3	7/14/17

10.13	Form of Stock Option Agreement under the Teladoc, Inc. 2017 Inducement Award Plan	10-K	001-37477	10.17	3/01/17

10.14	Form of Restricted Stock Agreement under the Teladoc, Inc. 2017 Inducement Award Plan	10-K	001-37477	10.18	3/01/17

10.15	Form of Restricted Stock Unit Agreement under the Teladoc, Inc. 2017 Inducement Award Plan	10-K	001-37477	10.19	3/01/17

10.16	Debt Commitment Letter, dated June 20, 2017, by and among Teladoc, Inc., Jefferies Group LLC and Jefferies Finance LLC.	8-K	001-37477	10.1	6/21/17

10.17	Credit Agreement, dated as of July 14, 2017, by and among Teladoc, Inc., as Borrower, the Lenders from time to time party thereto, Jefferies Finance LLC, as Administrative Agent and Collateral Agent, and Jefferies Finance LLC, as Sole Lead Arranger and Bookrunner.	8-K	001-37477	10.1	7/18/17
21.1	Subsidiaries of the Registrant.	S-1	333-204577	21.1	5/29/15

31.1	Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.					*

31.2	Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.					*